Bio-Rad Laboratories (BIO) 10-K 16 Feb 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Feb. 10, 2021	Jun. 30, 2020
Entity Registrant Name	BIO-RAD LABORATORIES, INC.
Document Type	10-K
Amendment Flag	false
Entity Central Index Key	0000012208
Current Fiscal Year End Date	--12-31
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Small Business	false
Entity Shell Company	false
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Document Annual Report	true
Document Period End Date	Dec. 31, 2020
Document Transition Report	false
Entity File Number	1-7928
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-1381833
Entity Address, Address Line One	1000 Alfred Nobel Drive,
Entity Address, City or Town	Hercules,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94547
City Area Code	(510)
Local Phone Number	724-7000
Entity Interactive Data Current	Yes
Common Class A [Member]
Entity Public Float			$ 9,501,744,303
Title of 12(b) Security	Class A Common Stock Par Value $0.0001 per share
Trading Symbol	BIO
Security Exchange Name	NYSE
Common Class A [Member] | Subsequent Event [Member]
Entity Common Stock, Shares Outstanding		24,768,670
Common Class B [Member]
Entity Public Float			$ 85,986,722
Title of 12(b) Security	Class B Common Stock Par Value $0.0001 per share
Trading Symbol	BIOb
Security Exchange Name	NYSE
Common Class B [Member] | Subsequent Event [Member]
Entity Common Stock, Shares Outstanding		5,075,386

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
ASSETS:
Cash and cash equivalents	$ 662,205	$ 660,672
Short-term investments	328,913	453,973
Restricted investments	5,560	5,560
Accounts Receivable, Allowance for Credit Loss	19,807	20,205
Accounts receivable, less allowance for doubtful accounts	419,424	392,672
Inventories:
Raw materials	126,911	109,570
Work in process	151,931	146,131
Finished goods	343,411	298,306
Total inventories	622,253	554,007
Prepaid expenses	90,621	102,331
Other current assets	10,859	10,940
Total current assets	2,139,835	2,180,155
Property, plant and equipment:
Land and improvements	25,739	25,215
Buildings and leasehold improvements	363,048	341,598
Equipment	1,063,974	1,015,359
Total property, plant and equipment	1,452,761	1,382,172
Less: accumulated depreciation and amortization	(961,390)	(882,833)
Property, plant and equipment, net	491,371	499,339
Operating lease right-of-use asset	202,136	201,868
Goodwill, net	291,916	264,131
Purchased intangibles, net	199,497	145,525
Other investments	9,561,140	4,638,205
Other assets	86,723	79,636
Total assets	12,972,618	8,008,859
LIABILITIES AND STOCKHOLDERS' EQUITY:
Accounts payable	139,451	107,014
Accrued payroll and employee benefits	222,875	180,084
Current maturities of long-term debt	1,798	426,172
Income taxes payable	23,282	8,763
Accrual for Taxes Other than Income Taxes, Current	34,053	27,522
Current operating lease liabilities	36,507	35,365
Deferred revenue	42,468	33,735
Other current liabilities	131,102	86,840
Total current liabilities	631,536	905,495
Long-term debt, net of current maturities	12,258	13,579
Deferred Income Tax Liabilities, Net	2,076,785	997,787
Operating lease liabilities	175,128	176,018
Other long-term liabilities	196,971	160,923
Total liabilities	3,092,678	2,253,802
Commitments and contingent liabilities
Preferred stock outstanding	0	0
Stockholders' equity:
Preferred stock	$ 0	$ 0
Additional paid-in capital	429,376	410,020
Retained earnings	9,268,012	5,470,779
Accumulated other comprehensive (loss) income	282,456	(87,348)
Stockholders' Equity Attributable to Parent	9,879,940	5,755,057
Total liabilities and stockholders' equity	$ 12,972,618	$ 8,008,859
Preferred stock authorized	7,500,000	7,500,000
Preferred stock par value	$ 0.0001	$ 0.0001
Preferred stock issued	0	0
Common Class A [Member]
Stockholders' equity:
Common stock	$ 2	$ 2
Common stock issued	25,072,619	24,966,035
Common stock outstanding	24,767,870	24,835,804
Common stock par value	$ 0.0001	$ 0.0001
Common stock authorized	80,000,000	80,000,000
Common Class B [Member]
Stockholders' equity:
Common stock	$ 1	$ 1
Common stock issued	5,076,186	5,089,532
Common stock outstanding	5,076,186	5,089,532
Common stock par value	$ 0.0001	$ 0.0001
Common stock authorized	20,000,000	20,000,000
Treasury Class-A [Member]
Stockholders' equity:
Treasury Stock, Value	$ (99,907)	$ (38,397)
Treasury Stock, Shares	304,749	130,231

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - shares	Dec. 31, 2020	Dec. 31, 2019
Preferred stock issued	0	0
Preferred stock outstanding	0	0

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Net sales	$ 2,545,626	$ 2,311,659	$ 2,289,415
Cost of Goods and Services Sold	1,107,804	1,054,663	1,066,264
Gross Profit	1,437,822	1,256,996	1,223,151
Selling, general and administrative expense	800,267	824,625	834,783
Research and development expense	226,598	202,710	199,196
Impairment losses on goodwill and long-lived assets	0	0	292,513
Income from operations	410,957	229,661	(103,341)
Interest expense	21,861	23,416	23,962
Foreign exchange losses, net	1,771	2,245	2,861
Unrealized Gain on Securities	(4,495,825)	(2,030,987)	(606,230)
Other (income) expense, net	(24,488)	(26,094)	(36,593)
Income before income taxes	4,907,638	2,261,081	512,659
Provision for income taxes	(1,101,371)	(502,406)	(147,045)
Net Income (Loss) Attributable to Parent	$ 3,806,267	$ 1,758,675	$ 365,614
Basic earnings per share:
Earnings Per Share, Basic	$ 127.86	$ 58.93	$ 12.25
Weighted average common shares - basic	29,768	29,843	29,836
Diluted earnings per share:
Earnings Per Share, Diluted	$ 126.20	$ 58.27	$ 12.10
Weighted average common shares - diluted	30,160	30,184	30,228

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Net Income (Loss) Attributable to Parent	$ 3,806,267	$ 1,758,675	$ 365,614
Foreign currency translation adjustments	371,057	(36,953)	(112,857)
Other post-employment benefits adjustments, net of tax	(3,806)	(7,363)	7,549
Net unrealized holding gains on available-for-sale investments, net of tax	2,553	3,926	(1,187)
Other comprehensive income, net of tax	369,804	(40,390)	(106,495)
Comprehensive income attributable to Bio-Rad	$ 4,176,071	$ 1,718,285	$ 259,119

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Cash received from customers	$ 2,531,135	$ 2,311,925	$ 2,326,310
Cash paid to suppliers and employees	(1,886,988)	(1,818,575)	(1,989,685)
Interest paid, net	(21,639)	(22,330)	(22,703)
Income tax payments, net	(65,244)	(45,081)	(62,414)
Investment proceeds and miscellaneous receipts, net	21,488	31,673	26,383
(Payments for) proceeds from foreign exchange contracts, net	(3,424)	285	7,603
Net cash provided by operating activities	575,328	457,897	285,494
Cash flows from investing activities:
Capital expenditures	(98,920)	(98,532)	(129,825)
Proceeds from dispositions of property, plant and equipment	70	129	4,315
Proceeds from Divestiture of a Division	12,240	0	6,964
Cash Acquired from Acquisition			266
Payments for Previous Acquisition	(96,655)	(79,386)
Recovery of (payments for) purchases of intangible assets	3,414	8,818	(3)
Payments for purchases of marketable securities and investments	(248,457)	(371,450)	(371,019)
Proceeds from sales of marketable securities and investments	89,734	104,632	77,029
Proceeds from maturities of marketable securities and investments	278,324	226,900	225,295
Net cash used in investing activities	(60,250)	(208,889)	(186,978)
Cash flows from financing activities:
Payments on long-term borrowings	(426,938)	(643)	(2,961)
Payments for credit agreement renewal fees	0	(486)	0
Proceeds from issuance of common shares for share-based compensation	20,198	13,113	14,133
Tax payments from net share settlement	(12,930)	(8,096)	(8,862)
Proceeds from Reissuance of Treasury Stock	0	3,831	0
Payments for purchases of treasury stock	(100,004)	(28,000)	(48,912)
Payments of contingent consideration	(3,367)	(2,477)	(2,078)
Net cash used in financing activities	(523,041)	(22,758)	(48,680)
Effect of foreign exchange rate changes on cash	12,427	2,237	(655)
Net increase in cash, cash equivalents and restricted cash	4,464	228,487	49,181
Beginning Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	662,651	434,164	384,983
Cash and cash equivalents	662,205	660,672	431,526
Restricted Cash included in Other current assets	3,994	93	111
Restricted Cash included in Other assets	916	1,886	2,527
Ending Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 667,115	$ 662,651	$ 434,164

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]
Balance at Dec. 31, 2017	$ 2,930,250	$ 3	$ 361,231	$ (217)	$ 1,830,439	$ 738,794
Balance (Accounting Standards Update 2014-09 [Member]) at Dec. 31, 2017	(136)	0	0	0	(136)	0
Balance (bio_AccountingStandardsUpdate201616Member) at Dec. 31, 2017	(17,591)	0	0	0	(17,591)	0
Balance (Accounting Standards Update 2016-01) at Dec. 31, 2017	864,490	0	0	0	1,543,747	(679,257)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	365,614	0	0	0	365,614	0
Other comprehensive income, net of tax	(106,495)	0	0	0	0	(106,495)
Issuance of common stock	5,271	0	5,271	0	0	0
Stock compensation expense	27,840	0	27,840	0	0	0
Treasury Stock, Value, Acquired, Cost Method	(48,912)	0	0	(48,912)	0	0
Balance at Dec. 31, 2018	4,020,331	3	394,342	(49,129)	3,722,073	(46,958)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,758,675	0	0	0	1,758,675	0
Other comprehensive income, net of tax	(40,390)	0	0	0	0	(40,390)
Issuance of common stock	5,017	0	5,017	0	0	0
Stock compensation expense	35,593	0	35,593	0	0	0
Treasury Stock, Value, Acquired, Cost Method	(28,000)	0	0	(28,000)	0	0
Stock Issued During Period, Value, Treasury Stock Reissued	(3,831)		(24,932)	(38,732)	(9,969)	0
Balance at Dec. 31, 2019	5,755,057	3	410,020	(38,397)	5,470,779	(87,348)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	3,806,267	0	0	0	3,806,267	0
Other comprehensive income, net of tax	369,804	0	0	0	0	369,804
Issuance of common stock	7,268	0	7,268	0	0	0
Stock compensation expense	41,556	0	41,556	0	0	0
Treasury Stock, Value, Acquired, Cost Method	(100,004)	0	0	(100,004)	0	0
Stock Issued During Period, Value, Treasury Stock Reissued	(8)	0	(29,468)	(38,494)	(9,034)	0
Balance at Dec. 31, 2020	$ 9,879,940	$ 3	$ 429,376	$ (99,907)	$ 9,268,012	$ 282,456

1. Significant Accounting Polic

1. Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies	SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash. Cash equivalents are stated at cost, which approximates fair value. Short-term Restricted Investments Short-term restricted investments of $5.6 million at both December 31, 2020 and 2019 represent a money market fund that is provided as collateral to secure worker's compensation and general liability insurance. Available-for-Sale Investments Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities and U.S. government sponsored agencies. Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date. Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations. Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data. Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect. On January 1, 2020, we adopted Accounting Standards Update (ASU) 2016-13 described below under "Recent Accounting Pronouncements Adopted." In accordance with the adopted guidance, we replaced the incurred loss approach with an expected loss model for instruments measured at amortized cost and we record allowances for available-for-sale debt securities rather than to reduce the carrying amount for other-than-temporary impairment as was followed under the other-than-temporary impairment model prior to January 1, 2020. Realized gains and losses and other-than-temporary impairments on investments are included in Other income and expense, net (see Note 10). Concentration of Credit Risk Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable. Cash and cash equivalents and investments are placed with various highly rated major financial institutions located in different geographic regions. The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements. We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions. In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end. Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas. We manage our accounts receivable credit risk through ongoing credit evaluation of our customers' financial conditions. We generally do not require collateral from our customers. Accounts Receivable and Allowance for Doubtful Accounts We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. On January 1, 2020 we adopted ASU 2016-13, "Measurement of Credit Losses on Financial Instruments" as described below and review our exposure to accounts receivable and reserve for amounts if collectability is no longer reasonably assured based on an assessment of various factors including historical loss rates and expectations of forward-looking loss estimates. Prior to January 1, 2020, the allowance for doubtful accounts was determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers' country or industry, historical losses and our customers' credit-worthiness. Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance. Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of the customer. Changes in our allowance for doubtful accounts were as follows (in millions): December 31, 2020 2019 2018 Beginning balance $ 20.2 $ 26.7 $ 25.5 Provision for expected credit losses (2020), bad debt (reversal) expense (2019 and 2018) 1.2 (1.2) 3.9 Write-offs charged against the allowance (1.6) (6.6) (2.7) Recoveries collected — 1.3 — Ending balance $ 19.8 $ 20.2 $ 26.7 Inventory Inventories are valued at the lower of cost and net realizable value and include material, labor and overhead costs. Cost is determined using standard costs, which approximate actual costs, and are relieved from inventory on a first-in, first-out or average cost basis. We classify our inventories based on our historical and anticipated levels of sales; any inventory in excess of its normal operating cycle (1 – 3 years depending on our product line) is classified as long-term on our consolidated balance sheets. The long-term inventory was immaterial as of December 31, 2020 and 2019. Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Additions and improvements are capitalized, and maintenance and repairs are expensed as incurred. Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets. The estimated useful lives of property, plant and equipment are generally as follows: buildings, 10-50 years; leasehold improvements, the life of the improvements or the term of the lease, whichever is shorter; reagent rental equipment, 1-5 years; and equipment, 3-12 years. When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are relieved from the accounts and the net gain or loss is included in operating expenses. Leases We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our Consolidated Balance Sheets. Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities in our Consolidated Balance Sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components. Where we act as lessor in our reagent rental arrangements, we allocate the consideration in the contract to the separate lease components and non-lease components. After allocation, the amount of variable payments allocated to lease components will be recognized as income under the lease accounting standard ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Such reagent rental arrangements are more fully described below under the caption "Reagent Rental Agreements." Intangible Assets Our intangible assets principally include goodwill, acquired technology / know how, license, tradenames and customer relationships. Intangible assets with finite lives, which include acquired technology / know how, tradenames, licenses and customer relationships, are carried at cost and amortized using the straight-line method over their useful lives ranging from 3 to 20 years. Intangible assets with indefinite lives, which include only goodwill, are recorded at cost and evaluated at least annually for impairment. Impairment of Long-Lived Assets We review long-lived assets, such as property, plant and equipment, and finite-lived intangible assets, for impairment whenever events indicate that the carrying amounts might not be recoverable. Recoverability of property, plant and equipment, and other finite-lived intangible asset is measured by comparing the projected undiscounted net cash flows associated with those assets to their carrying values. If an asset is considered impaired, it is written down to its fair value, which is determined based on the asset's projected discounted cash flows or appraised value, depending on the nature of the asset. For purposes of recognition of impairment for assets held for use, we group assets and liabilities at the lowest level for which cash flows are separately identifiable. For the year ended December 31, 2018, we impaired some finite-lived intangible assets in the amount of $10.5 million that were included in our Life Science segment's results of operations. There were no impairments of finite-lived intangible assets for the years ended December 31, 2020 and 2019. Impairment of Goodwill Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. We conduct a goodwill impairment analysis annually in the fourth quarter or more frequently if indicators of impairment exist or if a decision is made to sell or exit a business. Significant judgments are involved in determining if an indicator of impairment has occurred. Such indicators may include deterioration in general economic conditions, negative developments in equity and credit markets, adverse changes in the markets in which an entity operates, increases in input costs that have a negative effect on earnings and cash flows, or a trend of negative or declining cash flows over multiple periods, among others. The fair value that could be realized in an actual transaction may differ from that used to evaluate the impairment of goodwill. In reviewing goodwill for impairment, we have the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not (greater than 50%) that the estimated fair value of a reporting unit is less than its carrying amount. For the year ended December 31, 2020, we elected to perform a qualitative assessment and determined that an impairment was not more likely than not and no further analysis was required. We also may elect not to perform the qualitative assessment and, instead, proceed directly to the quantitative impairment test. The ultimate outcome of the goodwill impairment review for a reporting unit should be the same whether we choose to perform the qualitative assessment or proceed directly to the quantitative impairment test. For the year ended December 31, 2018, we impaired goodwill in the amount of $282.0 million, which was included in our Clinical Diagnostics and our Life Science segments' results of operations in the amounts of $276.1 million and $5.9 million, respectively. There was no impairment of goodwill for the years ended December 31, 2020 and 2019. Income Taxes We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities reflect the tax effects of net operating losses, tax credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which such temporary differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. We record deferred tax assets to the extent we believe these assets will more likely than not be realized. In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. When we establish or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement. The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes. On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities. In 2017, we recorded an income tax benefit of $70 million related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. We completed our accounting for the Tax Act under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) in 2018, which resulted in an additional income tax benefit of $49 million. Revenue Recognition We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recognized until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to customer specifications, which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control in relation to the equipment has occurred at that point as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon customer acceptance because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. In the fourth quarter of fiscal year 2020, we received $35.3 million in court awarded damages related to an intellectual property litigation for sales of products infringing on our patents during 2015 to 2018. Of the total amount, we recognized $32.3 million as revenue upon receipt of the damages based on the estimated stand-alone royalty rate associated with the infringed patents. Reagent Rental Agreements Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at lease commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. For purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the Company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Generally these arrangements do not contain an option for the lessee to purchase the underlying asset. We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Upon our adoption of ASC 842 in 2019, the maintenance services, along with the reagents, are now allocated to the non-lease elements and will be recognized as income in accordance with ASC 606. This change is in accordance with the requirements of ASC 842, and has resulted in a decrease in the amount of rental income and a corresponding increase in the amount of maintenance service revenue that is included in Net sales in our consolidated statements of income. Generally, the terms of the arrangements result in the transfer of control for reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments. Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate an immaterial amount of lease income. Our reported lease income is primarily variable in nature and is recognized upon delivery or as the reagents are consumed by the customer. Revenue allocated to the lease elements of these reagent rental arrangements represented approximately 3% of total revenue at both December 31, 2020 and 2019, respectively, and 5% at December 31, 2018, and are included as part of the Net sales in our consolidated statements of income. Contract costs: As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our consolidated statements of income. Disaggregation of Revenue: The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 14). Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements. The deferred revenue balance at December 31, 2020 and December 31, 2019 was $60.0 million and $45.8 million, respectively. The short-term deferred revenue balance at December 31, 2020 and December 31, 2019 was $42.5 million and $33.7 million, respectively. We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our consolidated statements of income. Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the Consolidated Balance Sheets. Change in our warranty liability were as follows (in millions): 2020 2019 2018 January 1 $ 9.0 $ 10.1 $ 18.7 Provision for warranty 9.4 9.9 25.5 Actual warranty costs (8.6) (11.0) (34.1) December 31 $ 9.8 $ 9.0 $ 10.1 Shipping and Handling We classify all freight costs billed to customers as Net sales. Related freight costs are recognized upon transfer of control of the promised products to customers as a fulfillment cost and included in Cost of goods sold. Research and Development All research and development costs are expensed as incurred. Types of expense incurred in research and development include materials and supplies, employee compensation, consulting and third-party services, depreciation, facility costs and information technology. Foreign Currency Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period. Income statement items are translated at average exchange rates for the period. The resulting translation adjustments are recorded as a separate component of stockholders’ equity. Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income. Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction. Forward Foreign Exchange Contracts As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income. Share-Based Compensation Plans Share-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value. We recognize these compensation costs over the requisite service period of the award, which is generally the vesting term of the share-based payment awards. Forfeitures are recognized as they occur. These plans are described more fully in Note 9. Earnings Per Share Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings per share calculation if the effect of including such securities would be anti-dilutive. The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands): Year Ended December 31, 2020 2019 2018 Basic weighted average shares outstanding 29,768 29,843 29,836 Effect of potentially dilutive stock options and restricted stock awards 392 341 392 Diluted weighted average common shares 30,160 30,184 30,228 Anti-dilutive stock options and restricted stock awards excluded from the computation of diluted EPS 44 98 84 Fair Value of Financial Instruments For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value. The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value. The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3). Equity Investments Investments in publicly traded companies in which we do not have the ability to exercise significant influence are reported at fair value, with unrealized gains and losses reported as a component of change in fair market value of equity securities in our consolidated statements of income. Companies in which we do not have a controlling financial interest, but over which we have significant influence, are accounted for using the equity method. Our share of the after-tax earnings of equity method investees is included in other income, net in our consolidated statements of income . Investments in privately held companies in which we do not have the ability to exercise significant influence are accounted for using the cost method with adjustments for observable changes in price or impairments (see Note 3). Recent Accounting Pronouncements Adopted In March 2020, the FASB issued ASU No. 2020-04, "Facilitation of the Effects of Reference Rate Reform on Financial Reporting (Topic 848)." The ASU provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate (e.g., LIBOR) reform if certain criteria are met, for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The ASU is effective as of March 12, 2020 through December 31, 2022. We will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. The ASU is currently not expected to have a material impact on our consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements," which aims to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing fair value measurement disclosures. We adopted this standard ef

2. Acquisitions

2. Acquisitions	12 Months Ended
	Dec. 31, 2020
Business Combinations [Abstract]
Mergers, Acquisitions and Dispositions Disclosures	2. ACQUISITIONS AND DIVESTITURES ACQUISITIONS Celsee Acquisition: On April 1, 2020 (the "Acquisition Date"), we acquired all equity interests of Celsee, Inc. ("Celsee") for total consideration of $99.3 million (as described in the table below), including the estimated fair value of contingent consideration. The contingent consideration of up to $60.0 million is payable in cash, upon the achievement of certain net revenues for the period beginning on January 1, 2021 and ending on December 31, 2022. Celsee is a manufacturer of instruments and consumables for the isolation, detection, and analysis of single cells. We believe this acquisition will complement our Life Science product offerings. The acquisition was included in our Life Science segment's results of operations from the Acquisition Date. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. Celsee met the definition of a business, and therefore is accounted for as a business combination. The fair value of consideration transferred for the Celsee acquisition consists of the following (in millions): Purchase price (cash) $ 99.2 Fair value of contingent consideration (earn-out) 0.1 Fair value of total consideration transferred $ 99.3 The following table summarizes the final fair values of the assets acquired and liabilities assumed at the Acquisition Date (in millions): Fair Value Cash and cash equivalents $ 0.6 Intangible assets 79.9 Deferred tax assets 8.4 Deferred tax liabilities (19.7) Other identifiable assets acquired, net 0.3 Net identifiable assets acquired 69.5 Goodwill 29.8 Net assets acquired $ 99.3 Goodwill related to the acquisition is primarily attributable to opportunities and economies of scale from combining the operations and technologies of Bio-Rad and Celsee, and is not deductible for tax purposes. The following table summarizes the final fair values and estimated useful lives of the components of identifiable intangible assets acquired as of the Acquisition Date (in millions): Fair Value Estimated Useful Life (years) Developed product technology $ 70.3 18.9 Customer relationships 3.6 4.0 Covenants not to compete 1.4 3.0 In-process research and development 4.6 Total identifiable intangible assets acquired $ 79.9 Intangible assets acquired as a result of the Celsee acquisition are being amortized over their estimated useful lives using the straight-line method of amortization, which materially approximates the distribution of the economic value of the identified intangible assets. Amortization of acquired developed technology of $2.8 million for the year ended December 31, 2020 is included in Cost of goods sold in the consolidated statements of income. Amortization of the acquired customer relationships of $0.7 million and covenants not to compete of $0.4 million for the year ended December 31, 2020 are included in Selling, general and administrative expense in the consolidated statements of income. In-process research and development (IPR&D) is accounted for as an indefinite-lived asset. Once the project is completed, the carrying value of the IPR&D will be amortized over the estimated useful life of the asset. IPR&D is assessed for impairment on an annual basis until the project is completed. We believe the values of acquired intangible assets reported above represent their fair values and approximate the amounts a market participant would pay for these intangible assets as of the Acquisition Date. We included Celsee's fair value of assets acquired and liabilities assumed in our consolidated balance sheets beginning on the Acquisition Date. The results of operations for Celsee subsequent to the Acquisition Date have been included in, but are immaterial to, our consolidated statements of income for the year ended. Pro forma results of operations for the Celsee acquisition have not been presented because they are not material to the condensed consolidated statements of income. Distributor Acquisition: In October 2019, we acquired all the issued and outstanding shares of a foreign distributor for approximately $4.2 million, which included cash payments at closing, net of closing cash, of $3.6 million, and $0.6 million in contingent consideration potentially payable to the sellers. In addition, we recorded a net gain of $0.4 million for the settlement of preexisting conditions concurrent with the acquisition that was recorded in Selling, general and administrative expense. The acquisition was included in our Clinical Diagnostics segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. Proforma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented. The final allocation of the payments was $3.4 million to customer relationships; a definite-lived intangible, $0.2 million to deferred tax asset, $0.8 million to deferred tax liability related to the purchased intangible and $1.4 million to acquired net assets. The final allocation of payments was unchanged from our preliminary allocation for the period ended December 31, 2019. Exact Diagnostics, LLC Acquisition: In August 2019, we acquired all the issued and outstanding membership interests of Exact Diagnostics, LLC for approximately $60.0 million. Cash payments at closing, net of closing cash, were $59.7 million. The acquisition was included in our Clinical Diagnostics segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is deductible for income tax purposes. Proforma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented. The final allocation of the payments was $26.8 million to purchased intangibles consisting primarily of customer relationships, developed product technology and tradenames, $4.2 million to acquired net assets, and $28.7 million to goodwill. We believe that the acquisition will accelerate market penetration in the areas of quality controls and assay verification panels in our Clinical Diagnostics operations. U.S. private company Acquisition: In March 2019, we completed the acquisition of all the issued and outstanding stock of a small U.S. private company for approximately $20.0 million. Cash payments, net of closing cash, consisted of $4.0 million paid in November 2018 and the remaining $16.0 million paid in March 2019. The acquisition was included in our Life Science segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is not deductible for income tax purposes. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented. The final allocation of the payments was $15.6 million to goodwill that included workforce and time-to-market advantage, $5.5 million to definite-lived intangibles, $0.2 million to in-process research and development, an indefinite-lived intangible asset, and a deferred tax liability of $1.3 million related to the purchased intangibles. During the year ended December 31, 2020, goodwill was decreased by $2.0 million due to the release from an escrow account setup during our acquisition, which should have been classified as a prepaid asset in its opening balance sheet as of acquisition date. We believe that the acquisition will expand our reagents suite of offerings in our Life Science operations. DIVESTITURE Informatics Divestiture: In April 2020, we received $12.2 million for the sale of our Informatics division, which focused on providing and developing comprehensive, high-quality spectral databases and associated software. The division was part of our Other Operations segment. In connection with this sale, we recorded an $11.7 million gain in Other income, net, in the consolidated statements of income for the year ended December 31, 2020.

3. Fair Value Measurements

3. Fair Value Measurements	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. FAIR VALUE MEASUREMENTS AND INVESTMENTS We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows: • Level 1: Quoted prices in active markets for identical instruments • Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) • Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments) Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2020 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 41.7 $ — $ 41.7 Time deposits 17.6 10.0 — 27.6 Asset-backed securities — 0.9 — 0.9 U.S. government sponsored agencies — 2.5 — 2.5 Money market funds 60.1 — — 60.1 Total cash equivalents (a) 77.7 55.1 — 132.8 Restricted investments (b) 6.7 — — 6.7 Equity Securities (c) 9,582.4 — — 9,582.4 Available-for-sale investments: Corporate debt securities — 133.2 — 133.2 U.S. government sponsored agencies — 76.9 — 76.9 Foreign government obligations — 4.0 — 4.0 Other foreign obligations — 2.1 — 2.1 Municipal obligations — 15.2 — 15.2 Asset-backed securities — 36.2 — 36.2 Total available-for-sale investments (d) — 267.6 — 267.6 Forward foreign exchange contracts (e) — 1.0 — 1.0 Total financial assets carried at fair value $ 9,666.8 $ 323.7 $ — $ 9,990.5 Financial liabilities carried at fair value: Forward foreign exchange contracts (f) $ — $ 1.0 $ — $ 1.0 Contingent consideration (g) — — 0.7 0.7 Total financial liabilities carried at fair value $ — $ 1.0 $ 0.7 $ 1.7 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2019 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 42.9 $ — $ 42.9 Time deposits 31.2 10.0 — 41.2 Asset-backed securities — 0.1 — 0.1 Money market funds 69.9 — — 69.9 Total cash equivalents (a) 101.1 53.0 — 154.1 Restricted investments (b) 5.6 — — 5.6 Equity securities (c) 4,664.4 — — 4,664.4 Available-for-sale investments: Corporate debt securities — 204.5 — 204.5 U.S. government sponsored agencies — 106.1 — 106.1 Foreign government obligations — 4.7 — 4.7 Other foreign obligations — 3.1 — 3.1 Municipal obligations — 11.6 — 11.6 Asset-backed securities — 72.9 — 72.9 Total available-for-sale investments (d) — 402.9 — 402.9 Forward foreign exchange contracts (e) — 0.9 — 0.9 Total financial assets carried at fair value $ 4,771.1 $ 456.8 $ — $ 5,227.9 Financial liabilities carried at fair value: Forward foreign exchange contracts (f) $ — $ 1.0 $ — $ 1.0 Contingent consideration (g) — — 4.9 4.9 Total financial liabilities carried at fair value $ — $ 1.0 $ 4.9 $ 5.9 (a) Cash equivalents are included in Cash and cash equivalents in the consolidated balance sheets. (b) Restricted investments are included in the following accounts in the consolidated balance sheets (in millions): December 31, 2020 December 31, 2019 Restricted investments $ 5.6 $ 5.6 Other investments 1.1 — Total $ 6.7 $ 5.6 (c) Equity securities are included in the following accounts in the consolidated balance sheets (in millions): December 31, 2020 December 31, 2019 Short-term investments $ 61.4 $ 51.0 Other investments 9,521.0 4,613.4 Total $ 9,582.4 $ 4,664.4 The change in fair market value on our equity securities for the year ended December 31, 2020 was $4,495.8 million gain, which was primarily due to our investment in Sartorius AG and is recorded in our consolidated statements of income. As of December 31, 2020, we own 12,987,900 ordinary voting shares and 9,588,908 preferenc e shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We did not purchase any incremental shares for the years ended December 31, 2020 and 2019. We own approximately 37% of the ordinary outstanding voting shares (excluding treasury shares) and 28% of the preference shares of Sartorius as of December 31, 2020. The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius' board of directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. (d) Available-for-sale investments are included in the following accounts in the consolidated balance sheets (in millions): December 31, December 31, 2019 Short-term investments $ 267.5 $ 402.8 Other investments 0.1 0.1 Total $ 267.6 $ 402.9 (e) Forward foreign exchange contracts in an asset position are included in other current assets in the consolidated balance sheets. (f) Forward foreign exchange contracts in a liability position are included in other current liabilities in the consolidated balance sheets. (g) Contingent consideration liabilities are included in the following accounts in the consolidated balance sheets (in millions): December 31, 2020 December 31, 2019 Other current liabilities $ 0.6 $ 3.3 Other long-term liabilities 0.1 1.6 Total $ 0.7 $ 4.9 During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel Labs. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount. We paid $3.3 million of sales milestone payments per the purchase agreement in 2020. All sales milestones have been fulfilled and the contingent consideration liability was accrued at its estimated fair value of $0 as of December 31, 2020. During the fourth quarter of 2019, we recognized a contingent consideration liability for earn-out targets related to our acquisition of a foreign distributor. The first earn-out payment of $0.7 million was paid by the acquisition date and the remaining payment is currently due and is anticipated to be paid in the first half of 2021. The maximum earn-out payment due is $1.4 million. The contingent consideration was accrued at its estimated fair value of $0.6 million as of December 31, 2020. During the second quarter of 2020, we recognized a contingent consideration liability upon our acquisition of Celsee, Inc. which represents the future potential earn-out payments of up to $60.0 million payable in cash upon the achievement of certain net revenues for the period beginning on January 1, 2021 and ending on December 31, 2022. The fair value of the earn-out as of the Acquisition Date was approximately $0.1 million which was determined by using a Black-Scholes-Merton option-pricing valuation model that includes significant assumptions and unobservable inputs such as the projected revenues of Celsee over the earn-out period and the probability of the earn-out threshold being met. The fair value of the contingent consideration is remeasured at each reporting period based on the assumptions and inputs on the date of remeasurement. The fair value of the earn-out was approximately $0.1 million as of December 31, 2020. The following table provides a reconciliation of the Level 3 contingent consideration liabilities measured at estimated fair value (in millions): December 31, 2019 $ 4.9 Analytical flow cytometer platform: Payment of sales milestone (3.3) Net decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense (1.0) Foreign distributor earn-outs: Change in estimated fair value of contingent consideration included in Selling, general and administrative expense — Celsee, Inc.: Fair value of contingent consideration 0.1 December 31, 2020 $ 0.7 To estimate the fair value of Level 2 debt securities as of December 31, 2020 and 2019, our primary pricing provider used Reuters as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Reuters does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source. Available-for-sale investments consist of the following (in millions): December 31, 2020 Amortized Unrealized Unrealized Allowances for Credit Losses Estimated Short-term investments: Corporate debt securities $ 130.5 $ 2.7 $ — — $ 133.2 Municipal obligations 15.0 0.2 — — 15.2 Asset-backed securities 35.8 0.3 — — 36.1 U.S. government sponsored agencies 74.7 2.2 — — 76.9 Foreign government obligations 4.0 — — — 4.0 Other foreign obligations 2.1 — — — 2.1 262.1 5.4 — — 267.5 Long-term investments: Asset-backed securities 0.1 — — — 0.1 0.1 — — — 0.1 Total $ 262.2 $ 5.4 $ — $ — $ 267.6 The following is a summary of the amortized cost and estimated fair value of our debt securities at December 31, 2020 by contractual maturity date (in millions): Amortized Estimated Fair Mature in less than one year $ 130.9 $ 131.5 Mature in one to five years 88.1 90.5 Mature in more than five years 43.2 45.6 Total $ 262.2 $ 267.6 Available-for-sale investments consist of the following (in millions): December 31, 2019 Amortized Unrealized Unrealized Estimated Short-term investments: Corporate debt securities $ 203.2 $ 1.4 $ (0.1) $ 204.5 Municipal obligations 11.5 0.1 — 11.6 Asset-backed securities 72.7 0.2 (0.1) 72.8 U.S. government sponsored agencies 105.6 0.7 (0.2) 106.1 Foreign government obligations 4.7 — — 4.7 Other foreign obligations 3.1 — — 3.1 400.8 2.4 (0.4) 402.8 Long-term investments: Asset-backed securities 0.1 — — 0.1 0.1 — — 0.1 Total $ 400.9 $ 2.4 $ (0.4) $ 402.9 The following is a summary of investments with gross unrealized losses and the associated fair value (in millions): There were no significant unrealized losses as of December 31, 2020 in either the less than or greater than 12 month categories. Gross unrealized losses and associated fair value (in millions) as of December 31, 2019 were: December 31, 2019 Less than 12 months Greater than 12 months Total Description of securities: Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 46.5 $ 0.1 $ 2.1 $ — $ 48.6 $ 0.1 Asset-backed securities 17.9 — 7.0 0.1 24.9 0.1 U.S. government sponsored agencies 27.5 0.2 10.8 — 38.3 0.2 Total $ 91.9 $ 0.3 $ 19.9 $ 0.1 $ 111.8 $ 0.4 As outlined in Note 1, we adopted ASU 2016-13 as of January 1, 2020. ASU 2016-13 replaced the incurred loss approach with an expected loss model for instruments measured at amortized cost and requires entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount as done under the former other-than-temporary impairment model. The factors we considered in our evaluation included t he extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis. At December 31, 2020, we have concluded that all payments related to our available-for-sale investments are expected to be made in full and on time at par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer. As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of December 31, 2020. Included in other current assets are $1.4 million and $2.0 million of interest receivable as of December 31, 2020 and December 31, 2019, respectively, primarily associated with securities in our available-for-sale investments portfolio. Associated interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the year ended December 31, 2020, we have not written-off any uncollected interest receivable. As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date. The notional principal amounts provide one measure of the transaction volume outstanding as of December 31, 2020 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties. The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in foreign exchange losses, net in the consolidated statements of income. The following is a summary of our forward foreign currency exchange contracts (in millions): December 31, 2020 Contracts maturing in January through March 2021 to sell foreign currency: Notional value $ 125.3 Unrealized loss $ (0.4) Contracts maturing in January through March 2021 to purchase foreign currency: Notional value $ 301.6 Unrealized gain $ 0.4 In December 2020, our 4.875% Senior Notes matured and were paid in full. See Note 5. The estimated fair value of our current maturities of long-term debt, excluding leases, as of December 31, 2019 that was not recognized at fair value in the consolidated balance sheets had an estimated fair value based on quoted market prices for the same or similar issues. The estimated fair value of our long-term debt and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions): December 31, 2020 December 31, 2019 Carrying Estimated Fair Value Hierarchy Level Carrying Estimated Fair Value Hierarchy Level Total current maturities long-term debt, excluding leases $ — $ — N/A $ 424.4 $ 435.5 2 Included in other investments in the consolidated balance sheet are investments without readily determinable fair value measured at cost with adjustments for observable price changes or impairments. The carrying value of these investments was $0.5 million and $0.3 million as of December 31, 2020 and December 31, 2019, respectively. Also included in other investments in the consolidated balance sheet are our equity method investments, for which our share of the equity method investees earnings is included in other income, net in our consolidated statements of income. The carrying value of these investments was $38.4 million and $24.3 million as of December 31, 2020 and December 31, 2019, respectively.

4. Intangible Assets, Goodwill

4. Intangible Assets, Goodwill and Other	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure	4. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS Changes to goodwill by segment were as follows (in millions): 2020 2019 Life Clinical Total Life Clinical Total Balances as of January 1: Goodwill $ 250.1 $ 349.2 $ 599.3 $ 234.5 $ 320.5 $ 555.0 Accumulated impairment losses and write-offs (41.8) (293.4) (335.2) (41.8) (293.4) (335.2) Goodwill, net 208.3 55.8 264.1 192.7 27.1 219.8 Acquisitions (see Note 2) 29.8 — 29.8 15.6 28.7 44.3 Other adjustments (see Note 2) (2.0) — (2.0) — — — Period increase, net 27.8 — 27.8 15.6 28.7 44.3 Balances as of December 31: Goodwill 277.9 349.2 627.1 250.1 349.2 599.3 Accumulated impairment losses and write-offs (41.8) (293.4) (335.2) (41.8) (293.4) (335.2) Goodwill, net $ 236.1 $ 55.8 $ 291.9 $ 208.3 $ 55.8 $ 264.1 Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions): December 31, 2020 Weighted-Average Amortization Period (years) Purchase Accumulated Net Customer relationships/lists 5.51 $ 116.6 $ (87.2) $ 29.4 Know how 4.75 196.6 (175.4) 21.2 Developed product technology 14.00 218.1 (107.1) 111.0 Licenses 7.73 65.6 (37.4) 28.2 Tradenames 7.82 6.6 (4.2) 2.4 Covenants not to compete 3.87 4.5 (2.0) 2.5 Other — 0.1 (0.1) — Total definite-lived intangible assets 608.1 (413.4) 194.7 In-process research and development 4.8 — 4.8 Total purchased intangible assets $ 612.9 $ (413.4) $ 199.5 December 31, 2019 Weighted-Average Amortization Period (years) Purchase Accumulated Net Customer relationships/lists 6.36 $ 107.2 $ (74.3) $ 32.9 Know how 5.71 188.5 (162.6) 25.9 Developed product technology 8.31 144.2 (93.9) 50.3 Licenses 8.74 76.0 (44.4) 31.6 Tradenames 8.50 6.4 (3.6) 2.8 Covenants not to compete 6.01 3.2 (1.4) 1.8 Other — 0.1 (0.1) — Total definite-lived intangible assets 525.6 (380.3) 145.3 In-process research and development 0.2 — 0.2 Total purchased intangible assets $ 525.8 $ (380.3) $ 145.5 No impairment losses related to goodwill and purchased intangibles were recorded in 2020 and 2019. Amortization expense related to purchased intangible assets for the years ended December 31, 2020, 2019 and 2018 was $27.5 million, $23.5 million and $28.3 million, respectively. Estimated future amortization expense (based on existing purchased intangible assets) for the years ending December 31, 2021, 2022, 2023, 2024, 2025 and thereafter is $28.3 million, $25.1 million, $23.8 million, $20.7 million, $18.7 million, and $78.1 million, respectively.

5. Notes Payable and Long-Term

5. Notes Payable and Long-Term Debt	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Notes Payable and Long-term Debt	NOTES PAYABLE AND LONG-TERM DEBT Under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had $207.2 million available for borrowing and usage as of December 31, 2020, which was reduced by $4.9 million that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations. The principal components of long-term debt are as follows (in millions): December 31, 2020 December 31, 2019 4.875% Senior Notes due 2020, net of discount $ — $ 425.0 Less unamortized discount and debt issuance costs — (0.6) Long-term debt less unamortized discount and debt issuance costs — 424.4 Finance leases and other debt 14.1 15.4 14.1 439.8 Less current maturities (1.8) (426.2) Long-term debt $ 12.3 $ 13.6 4.875% Senior Notes In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due December 2020 (4.875% Notes). The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946%. The 4.875% Notes paid a fixed rate of interest of 4.875% per year. We had the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date. Our obligations under the 4.875% Notes were not secured and ranked equal in right of payment with all of our existing and future unsubordinated indebtedness. Certain covenants applied at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. There were no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios. We were in compliance with required debt covenants as of December 31, 2019, and in December 2020 the 4.875% Notes were paid in full, including accrued interest. Credit Agreement In April 2019, Bio-Rad entered into a $200.0 million unsecured revolving credit facility ("Credit Agreement"). Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of December 31, 2020; however, $0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability as of December 31, 2020. The Credit Agreement matures in April 2024. If we had borrowed against our Credit Agreement, the borrowing rate would have been 1.375% at December 31, 2020, which is based on the 3-month LIBOR. The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens. We were in compliance with all of these ratios and covenants as of December 31, 2020 and 2019. Maturities of finance leases and other debt at December 31, 2020 were as follows: 2021 - $1.8 million; 2022 - $1.8 million; 2023 - $0.4 million; 2024 - $0.4 million; 2025 - $0.4 million; and 2026 and thereafter - $9.3 million.

6. Income Taxes

6. Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes [Text Block]	6. INCOME TAXES The U.S. and international components of income before taxes are as follows (in millions): Year Ended December 31, 2020 2019 2018 U.S. $ 2,339.7 $ 1,034.0 $ 363.4 International 2,567.9 1,227.1 149.3 Income before taxes $ 4,907.6 $ 2,261.1 $ 512.7 The provision for income taxes consists of the following (in millions): Year Ended December 31, 2020 2019 2018 Current tax expense: U.S. Federal $ 69.9 $ 13.0 $ 8.8 State 12.0 4.4 2.2 International 22.3 23.5 30.5 Current tax expense 104.2 40.9 41.5 Deferred tax expense: U.S. Federal 893.5 409.7 114.0 State 54.0 24.4 6.6 International 31.5 16.1 0.3 Deferred tax expense 979.0 450.2 120.9 Non-current tax expense (benefit) 18.2 11.3 (15.4) Provision for income taxes $ 1,101.4 $ 502.4 $ 147.0 The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows: Year Ended December 31, 2020 2019 2018 U. S. statutory tax rate 21.0 % 21.0 % 21.0 % Impact of foreign operations (9.9) (9.7) (4.1) Goodwill impairment — — 5.6 U.S. taxation of foreign income 10.2 10.3 15.5 U.S. tax reform — — (9.6) State taxes 1.1 1.0 1.7 Other — (0.4) (1.4) Provision for income taxes 22.4 % 22.2 % 28.7 % On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities. In 2017, we recorded an income tax benefit of $70 million related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. We completed our accounting for the Tax Act under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) in 2018, which resulted in an additional income tax benefit of $49 million. Our effective income tax rates were 22.4%, 22.2% and 28.7% for the years ended December 31, 2020, 2019 and 2018, respectively. The effective tax rates for the years ended December 31, 2020 and 2019 were driven by the unrealized gain in equity securities that is taxed at approximately 22% as well as the geographic mix of earnings and the taxation of our foreign earnings. The effective tax rate for the year ended December 31, 2018 was driven by detriments due to non-deductible impairment charges and the taxation of our foreign operations, partially offset by a $49 million benefit recorded as a result of the completion of our accounting for the Tax Act under SAB 118. Many jurisdictions in which we operate have statutory tax rates that differ from the U.S. statutory tax rate of 21%. Our effective tax rate is impacted, either favorably or unfavorably, by many factors including, but not limited to the jurisdictional mix of income before tax, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits. Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of deferred tax assets and liabilities are as follows (in millions): December 31, 2020 2019 Deferred tax assets: Bad debt, inventory and warranty accruals $ 29.6 $ 23.9 Other post-employment benefits, vacation and other reserves 29.8 23.0 Tax credit and net operating loss carryforwards 93.5 83.7 Lease obligations 49.3 48.6 Other 44.8 26.0 Total gross deferred tax assets 247.0 205.2 Valuation allowance (44.6) (67.2) Total deferred tax assets 202.4 138.0 Deferred tax liabilities: Property and equipment 37.0 38.4 Lease assets 46.8 46.4 Investments and intangible assets 2,143.4 1,001.4 Total deferred tax liabilities 2,227.2 1,086.2 Net deferred tax liabilities $ (2,024.8) $ (948.2) The realization of deferred tax assets is dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that our California and certain foreign deferred tax assets will not be realized as of December 31, 2020, and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our deferred tax assets in California and certain foreign jurisdictions decreased by $22.6 million for the year ended December 31, 2020. The valuation allowance for deferred tax assets is as follows (in millions): December 31, 2020 2019 2018 Beginning balance $ 67.2 $ 70.8 $ 66.4 Additions charged to expenses — — 4.4 Deductions from reserves (22.6) (3.6) — Ending balance $ 44.6 $ 67.2 $ 70.8 As of December 31, 2020, our federal, state and foreign net operating loss carryforwards were approximately $26.3 million, $64.5 million and $255.0 million, respectively. Of our foreign net operating losses, $117.8 million may be carried forward indefinitely. The majority of the remaining foreign net operating losses, if not utilized, will begin to expire in 2025. Our federal and state net operating loss carryforwards, if not utilized, will begin to expire in 2028. As of December 31, 2020, our federal and state tax credit carryforwards were approximately $2.3 million and $37.2 million, respectively. Our federal tax credits, if not utilized, will begin to expire in 2029, and our state tax credits, generally, may be carried forward indefinitely. Federal and state tax laws impose restrictions on the utilization of net operating loss and certain tax credit carryforwards in the event of a change in our ownership as defined by the Internal Revenue Code Sections 382 and 383. Under Section 382 and 383 of the Internal Revenue Code, substantial changes in our ownership and the ownership of acquired companies may limit the amount of net operating loss and research and development credit carryforwards that are available to offset taxable income. The annual limitation would not automatically result in the loss of net operating loss or research and development credit carryforwards but may limit the amount available in any given future period. Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2012 and forward for the U.S. and certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period. The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions): 2020 2019 2018 Unrecognized tax benefits – January 1 $ 39.2 $ 29.8 $ 54.9 Additions to tax positions related to prior years 14.0 7.6 0.6 Reductions to tax positions related to prior years (1.5) (0.7) (20.2) Additions to tax positions related to the current year 3.4 3.0 4.6 Settlements — — (6.8) Lapse of statute of limitations (0.6) (0.4) (1.1) Currency translation 1.3 (0.1) (2.2) Unrecognized tax benefits – December 31 $ 55.8 $ 39.2 $ 29.8 Bio-Rad recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. Related to the unrecognized tax benefits noted above, the cumulative amount of accrued interest and penalties as of December 31, 2020, 2019 and 2018 was $14.3 million, $11.2 million and $9.5 million, respectively. Bio-Rad accrued interest and penalties of $2.8 million, $1.7 million, and $(1.4) million for the years ended December 31, 2020, 2019, and 2018, respectively. The total unrecognized tax benefits and interest and penalties of $70.1 million as of December 31, 2020 was partially offset by deferred tax assets of $1.5 million and prepaid taxes of $5.8 million, for a net amount of $62.8 million. As of December 31, 2020, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $17.2 million. Substantially all such amounts will impact our effective income tax rate if recognized. It is generally our intention to repatriate certain foreign earnings to the extent that such repatriations are not restricted by local laws or accounting rules, and there are no substantial incremental costs. The determination of the amount of the unrecognized deferred tax liability for foreign earnings that are indefinitely reinvested is not practicable to estimate.

7. Stockholders' Equity

7. Stockholders' Equity	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	7. STOCKHOLDERS' EQUITY Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B). Each share of Class A and Class B participates equally in the earnings of Bio-Rad, and is identical in all respects except as follows. Class A has limited voting rights. Each share of Class A is entitled to one tenth of a vote on most matters, and each share of Class B is entitled to one vote. Additionally, Class A stockholders are entitled to elect 25% of the directors, with Class B stockholders electing the remaining directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares but no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares. Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder. The founders of Bio-Rad, the Schwartz family, collectively hold a majority of Bio-Rad’s voting stock. As a result, the Schwartz family is able to exercise significant influence over Bio-Rad. Changes to Bio-Rad's issued common stock shares are as follows (in thousands): Class A Shares Class B Shares Balance at January 1, 2018 24,679 5,108 Class B to Class A conversions 30 (30) Issuance of common stock 175 18 Balance at December 31, 2018 24,884 5,096 Class B to Class A conversions 24 (24) Issuance of common stock 58 18 Balance at December 31, 2019 24,966 5,090 Class B to Class A conversions 32 (32) Issuance of common stock 75 18 Balance at December 31, 2020 25,073 5,076 Treasury Shares In November 2017, the Board of Directors authorized a share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to $250.0 million of outstanding shares of our common stock. In July 2020, the Board of Directors authorized increasing the Share Repurchase Program to allow the Company to repurchase up to an additional $200.0 million of stock. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. The share repurchase activity under the share repurchase program through open market transactions for the years ended December 31, 2020, 2019 and 2018 are summarized as follows: Number of Shares Purchased Weighted-Average Price per Share Total Shares Repurchased To Date Remaining Authorized Value November 1, 2018 - November 30, 2018 178,911 $ 273.39 193,150 $ 201.1 May 1, 2019 - May 31, 2019 25,421 $ 291.70 218,571 $ 193.7 June 1, 2019 - June 30, 2019 25,977 $ 292.01 244,548 $ 186.1 August 1, 2019 - August 31, 2019 14,745 $ 339.05 259,293 $ 181.1 November 1, 2019 - November 30, 2019 22,343 $ 358.04 281,636 $ 173.1 March 1, 2020 - March 31, 2020 291,941 $ 342.55 573,577 $ 73.1 For the years ended December 31, 2020 and 2019, we used 117,423 and 118,910, respectively, of the repurchased shares in connection with the vesting of restricted stock units and in 2019 we used 19,755 shares in connection with ESPP stock purchases. As of December 31, 2020, $273.1 million remained under the Share Repurchase Program.

8. Accumulated Other Comprehens

8. Accumulated Other Comprehensive Income	12 Months Ended
	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
accumulated other comprehensive income [Text Block]	8. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Accumulated other comprehensive income (loss) included in our consolidated balance sheets and consolidated statements of changes in stockholders' equity consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains (losses) on available-for-sale investments Total Accumulated other comprehensive income (loss) Balances as of January 1, 2019 $ (35.5) $ (14.8) $ 3.3 $ (47.0) Other comprehensive (loss) income, before reclassifications (36.5) (10.0) 4.8 (41.7) Amounts reclassified from Accumulated other comprehensive income — 1.5 (0.4) 1.1 Income tax effects (0.4) 1.1 (0.5) 0.2 Other comprehensive income (loss), net of income taxes (36.9) (7.4) 3.9 (40.4) Balances as of December 31, 2019 $ (72.4) $ (22.2) $ 7.2 $ (87.4) Other comprehensive income (loss), before reclassifications 371.9 (5.3) 4.0 370.6 Amounts reclassified from Accumulated other comprehensive income — 0.3 (0.6) (0.3) Income tax effects (0.9) 1.2 (0.8) (0.5) Other comprehensive income (loss), net of income taxes 371.0 (3.8) 2.6 369.8 Balances as of December 31, 2020 $ 298.6 $ (26.0) $ 9.8 $ 282.4 All amounts reclassified out of accumulated other comprehensive income were reclassified into other income, net in the consolidated statements of income. Reclassification adjustments are calculated using the specific identification method.
Comprehensive Income (Loss) Note	ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Accumulated other comprehensive income (loss) included in our consolidated balance sheets and consolidated statements of changes in stockholders' equity consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains (losses) on available-for-sale investments Total Accumulated other comprehensive income (loss) Balances as of January 1, 2019 $ (35.5) $ (14.8) $ 3.3 $ (47.0) Other comprehensive (loss) income, before reclassifications (36.5) (10.0) 4.8 (41.7) Amounts reclassified from Accumulated other comprehensive income — 1.5 (0.4) 1.1 Income tax effects (0.4) 1.1 (0.5) 0.2 Other comprehensive income (loss), net of income taxes (36.9) (7.4) 3.9 (40.4) Balances as of December 31, 2019 $ (72.4) $ (22.2) $ 7.2 $ (87.4) Other comprehensive income (loss), before reclassifications 371.9 (5.3) 4.0 370.6 Amounts reclassified from Accumulated other comprehensive income — 0.3 (0.6) (0.3) Income tax effects (0.9) 1.2 (0.8) (0.5) Other comprehensive income (loss), net of income taxes 371.0 (3.8) 2.6 369.8 Balances as of December 31, 2020 $ 298.6 $ (26.0) $ 9.8 $ 282.4 All amounts reclassified out of accumulated other comprehensive income were reclassified into other income, net in the consolidated statements of income. Reclassification adjustments are calculated using the specific identification method.

9. Share-based Compensation

9. Share-based Compensation	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement, Noncash Expense [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments	9. SHARE-BASED COMPENSATION/EQUITY AWARD AND PURCHASE PLANS Equity Award Plan We have the 2017 Incentive Award Plan (2017 Plan) for officers and certain other employees. The 2017 Plan authorizes the grant of stock options, restricted stock, restricted stock units, and other types of equity awards to employees. Stock options are granted at exercise prices not less than the fair market value of the underlying common stock on the date of grant and have a maximum term of 10 years. We may issue stock options for either Class A or Class B common stock. Prior to September 2020 grants, equity awards granted vest in increments of 20% per year on the yearly anniversary date of the grant. Starting in September 2020, equity awards granted vest in increments of 25% per year on the yearly anniversary date of the grant. A total of 2,108,050 shares have been reserved for issuance of equity awards under the 2017 Plan and may be of either Class A or Class B common stock. At December 31, 2020, there were 1,451,617 shares available to be granted. Employee Stock Purchase Plans Our 2011 Employee Stock Purchase Plan (2011 ESPP) provides that eligible employees may contribute up to the greater of 10% of their compensation or $25,000 annually towards the quarterly purchase of our Class A common stock. The employees’ purchase price is 85% of the lesser of the fair market value of the stock on the first business day or the last business day of each calendar quarter. We have authorized the sale of 1,300,000 shares of Class A common stock under the 2011 ESPP. Share-Based Compensation Included in our share-based compensation expense is the cost related to stock option grants, ESPP stock purchases and restricted stock unit awards. Share-based compensation expense is allocated to Cost of goods sold, Selling, general and administrative expense, and Research and development expense in the Consolidated Statements of Income. For the year ended December 31, 2020, we recognized share-based compensation expense of $41.6 million of which $3.4 million was allocated to Cost of goods sold, $31.8 million was allocated to Selling general and administrative expense, and $6.4 million was allocated to Research and development expense. For the year ended December 31, 2019, we recognized share-based compensation expense of $35.6 million of which $2.9 million was allocated to Cost of goods sold, $27.9 million was allocated to Selling general and administrative expense, and $4.8 million was allocated to Research and development expense. For the year ended December 31, 2018, we recognized share-based compensation expense of $27.8 million, of which $2.3 million was allocated to Cost of goods sold, $22.0 million was allocated to Selling general and administrative expense, and $3.5 million was allocated to Research and development expense. The income tax benefit related to share-based compensation expense was $6.0 million, $5.6 million and $4.4 million for the years ended December 31, 2020, 2019 and 2018, respectively. We did not capitalize any share-based compensation expense in inventory as it was immaterial. The tax benefit from equity awards vested or exercised during the years ended December 31, 2020, 2019 and 2018 was $11.2 million, $5.4 million, and $5.4 million, respectively. For equity awards, we amortize the fair value on a straight-line basis. All equity awards are amortized over the requisite service periods of the awards, which are generally the vesting periods. We recognize forfeitures as they occur. Stock Options The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions: Year Ended December 31, 2020 2019 2018 Expected volatility 27 % 22 % 22 % Risk-free interest rate 0.31 % 1.69 % 2.85 % Expected life (in years) 7.4 7.5 7.6 Expected dividend — — — Weighted-average fair value of options granted $ 153.32 $ 93.96 $ 105.94 Expected volatility is based on the historical volatilities of our common stock for a period equal to the stock option’s expected life. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the number of years that we estimate, based primarily on historical experience, that the options will be outstanding prior to exercise. We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero. The following table summarizes stock option activity: Shares Weighted- Weighted- Aggregate Outstanding, December 31, 2019 344,522 $ 162.23 Granted 22,527 $ 524.30 Exercised (66,085) $ 112.96 Forfeited (15,841) $ 269.64 Outstanding, December 31, 2020 285,123 $ 196.29 4.64 $ 110.2 Unvested, December 31, 2020 73,126 $ 364.07 8.35 $ 16.0 Exercisable, December 31, 2020 211,997 $ 138.42 3.36 $ 94.2 Intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic value on the date of exercise of stock options exercised during the years ended December 31, 2020, 2019 and 2018 was approximately $24 million, $12 million and $8 million, respectively. Cash received from stock options exercised during the years ended December 31, 2020, 2019 and 2018 was $3.8 million, $2.6 million and $0.5 million, respectively. As of December 31, 2020, there was $7.0 million of total unrecognized compensation cost from stock options. This amount is expected to be recognized in the future over a remaining weighted-average period of approximately three years. Restricted Stock Units Restricted stock units are rights to receive shares of company stock. The fair value of a restricted stock unit is the market value as determined by the closing price of the stock on the day of grant. The following table summarizes restricted stock unit activity: Weighted- Weighted-Average Aggregate Outstanding, December 31, 2019 469,942 $ 279.14 Granted 112,162 $ 523.64 Vested (132,745) $ 246.88 Forfeited (62,976) $ 280.97 Outstanding, December 31, 2020 386,383 $ 360.90 1.85 $ 225.2 The total fair value of restricted stock units vested for the years ended December 31, 2020, 2019 and 2018 was $65.0 million, $44.8 million and $40 million, respectively. As of December 31, 2020, there was approximately $125.6 million of total unrecognized compensation cost related to restricted stock units. This amount is expected to be recognized over a remaining weighted-average period of approximately three years. Employee Stock Purchase Plans The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions: Year Ended December 31, 2020 2019 2018 Expected volatility 41 % 31 % 27 % Risk-free interest rate 0.5 % 2.25 % 1.82 % Expected life (in years) 0.25 0.25 0.25 Expected dividend — — — Weighted-average fair value of purchase rights $ 94.93 $ 60.39 $ 55.04 The major assumptions are primarily based on historical data. Volatility is based on the historical volatilities of our common stock for a period equal to the expected life of the purchase rights. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero. We sold 47,548 shares for total employee contributions of $16.4 million, 58,717 shares for total employee contributions of $14.3 million and 63,464 shares for total employee contributions of $13.6 million under the 2011 ESPP to employees for the years ended December 31, 2020, 2019 and 2018, respectively. At December 31, 2020, 551,983 shares remain authorized and available for issuance under the 2011 ESPP.

10. Other Income and Expenses

10. Other Income and Expenses	12 Months Ended
	Dec. 31, 2020
Other Income and Expenses [Abstract]
Other Income and Other Expense Disclosure	10. OTHER INCOME AND EXPENSE, NET Other (income) expense, net includes the following components (in millions): Year Ended December 31, 2020 2019 2018 Interest and investment income $ (18.2) $ (30.5) $ (26.6) Net realized gains on investments (1.0) (1.5) (1.6) Other-than-temporary impairment losses on investments 4.6 5.8 0.8 Gain on sale of land — — (4.1) Gain on divestiture of a division (11.7) — (5.1) Other expense 1.8 0.1 — Other income, net $ (24.5) $ (26.1) $ (36.6) Other-than-temporary impairment losses on equity method investments were recorded in light of the investees' financial condition.

11. Supplemental Cash Flow Info

11. Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2020
Supplemental Cash Flow Information [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	11. SUPPLEMENTAL CASH FLOW INFORMATION The reconciliation of net income to net cash provided by operating activities is as follows (in millions): Year Ended December 31, 2020 2019 2018 Net income $ 3,806.3 $ 1,758.7 $ 365.6 Adjustments to reconcile net income to net cash provided by operating activities Depreciation and amortization 138.1 134.2 138.1 Reduction in the carrying amount of right-of-use assets 37.1 40.3 — Share-based compensation 41.6 35.6 27.8 Gains on dispositions of securities (0.7) (1.5) (1.6) Other-than-temporary impairment losses on investments 4.6 5.8 0.8 Changes in fair market value of equity securities (4,495.8) (2,031.0) (606.2) Losses on dispositions of fixed assets 1.1 1.2 2.0 Gain on sale of land — — (4.1) Gain on divestiture of a division (11.7) — (5.1) Payments for operating lease liabilities (36.5) (38.6) — Changes in fair value of contingent consideration (1.0) (1.6) (6.2) (Increase) decrease in accounts receivable, net (15.0) 1.6 59.7 (Increase) decrease in inventories, net (52.1) 24.2 (12.9) (Increase) decrease in other current assets (8.4) 61.8 (15.3) Increase (decrease) in accounts payable and other current liabilities 124.7 10.6 (45.6) Increase (decrease) in income taxes payable 39.0 (4.2) (20.9) Increase in deferred income taxes 978.9 450.2 120.9 (Increase) decrease in other long term assets (6.4) (1.7) 1.1 Increase (decrease) in other long term liabilities 26.9 13.4 (10.0) Impairment losses on goodwill and long-lived assets — — 292.5 Other 4.6 (1.1) 4.9 Net cash provided by operating activities $ 575.3 $ 457.9 $ 285.5 Non-cash investing activities: Purchased property, plant and equipment $ 1.2 $ 8.1 $ 5.7 Purchased marketable securities and investments $ 4.6 $ 1.4 $ 0.8 Sold marketable securities and investments $ — $ 1.3 $ —

12. Commitments & Contingent Li

12. Commitments & Contingent Liabilities	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	12. COMMITMENTS AND CONTINGENT LIABILITIES Deferred Profit Sharing Retirement Plan We have a profit sharing plan covering substantially all U.S. employees. Contributions are made at the discretion of management. Bio-Rad has no liability other than for the current year’s contribution. Contribution expense was $10.6 million, $16.1 million and $15.9 million for the years ended December 31, 2020, 2019 and 2018, respectively. Purchase Obligations As of December 31, 2020, we had purchase obligations that have not been recognized on our balance sheet of $16.6 million, which include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty. Recognition of purchase obligations occurs when products or services are delivered to Bio-Rad. The annual future fixed and determinable portion of our purchase obligations that have not been recognized on our balance sheet as of December 31, 2020 are as follows: 2021 - $14.1 million, 2022 - $2.1 million , 2023 - $0.1 million, 2024 - $0.1 million, 2025 - $0.1 million and after 2025 - $0.1 million. Long-Term Liabilities As of December 31, 2020, we had obligations that have been recognized on our balance sheet of $134.0 million, which primarily represent recognized long-term obligations for other post-employment benefits as indicated below that are mostly due in more than 5 years, and long-term deferred revenue. Excluded are tax liabilities for uncertain tax positions and contingencies. We are not able to reasonably estimate the timing of future cash flows of these tax liabilities, therefore, our income tax obligations are excluded. The annual future fixed and determinable portion of our obligations that have been recognized on our balance sheet as of December 31, 2020 were as follows: 2021 - $2.7 million , 2022 - $12.0 million, 2023 - $7.3 million, 2024 - $5.6 million, 2025 - $3.8 million and after 2025 - $102.6 million. Letters of Credit/Guarantees In the ordinary course of business, we are at times required to post letters of credit/guarantees. The letters of credit/guarantees are issued by financial institutions to guarantee our obligations to various parties. We were contingently liable for $4.9 million of standby letters of credit/guarantees with financial institutions as of December 31, 2020. Other Post-Employment Benefits In several foreign locations we are statutorily required to provide retirement benefits or a lump sum termination indemnity to our employees upon termination for virtually any reason. These plans are accounted for as defined benefit plans and the associated net benefit obligation as of December 31, 2020 and 2019 of $96.1 million and $81.5 million, respectively, has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets. Most plans are not required to be funded, and as such, there is no trust or other device used to accumulate assets or settle these obligations. However, some of these plans require funding based on local laws in which there is a trust or other device administered by an external plan manager that is used to accumulate assets to assist in settling these obligations. The following disclosures include such plans, which are located in France, Switzerland, Germany, Korea, India, Thailand, Italy, Dubai and Japan. Obligations and Funded Status The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in the Consolidated Balance Sheets for the plans (in millions): Change in benefit obligation: 2020 2019 Benefit obligation at beginning of year $153.8 $137.3 Service cost 7.8 6.9 Interest cost 0.8 1.5 Plan participants' contributions 4.1 3.5 Actuarial loss 5.3 11.9 Gross benefits paid (1.7) (2.1) Plan amendments — 0.2 Settlements (6.4) (3.8) Change attributable to foreign exchange 13.8 (1.6) Benefit obligation at end of year 177.5 153.8 Change in plan assets: Fair value of plan assets at beginning year 72.3 66.9 Actual return on plan assets 0.6 0.9 Employer contributions 4.1 4.7 Plan participants' contributions 4.0 3.8 Gross benefits paid 0.2 (0.8) Settlements (6.4) (3.8) Change attributable to foreign exchange 6.6 0.6 Fair value of plan assets at end of year 81.4 72.3 Under funded status of plans $(96.1) $(81.5) Amounts recognized in the consolidated balance sheets: Current liabilities (Accrued payroll and employee benefits) $(1.3) $(1.1) Noncurrent liabilities (Other long-term liabilities) (94.8) (80.4) Net liability, end of fiscal year $(96.1) $(81.5) Components of Net Periodic Benefit Cost The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions): 2020 2019 2018 Service costs $7.8 $6.9 $7.5 Interest costs 0.8 1.5 1.1 Expected returns on plan assets (0.7) (1.2) (1.1) Amortization of actuarial losses 1.3 1.0 1.3 Amortization of prior service costs — — 0.1 Settlements 1.3 0.9 — Net periodic benefit costs $10.5 $9.1 $8.9 Assumptions The above actuarial net losses were primarily based on financial, demographic and experience assumptions. The weighted-average assumptions used in computing the benefit obligations are as follows: 2020 2019 Discount rate 0.3 % 0.5 % Compensation rate increase 1.7 % 1.7 % The weighted-average assumptions used in computing the net periodic benefit costs are as follows: 2020 2019 2018 Discount rate 0.5 % 1.1 % 0.8 % Expected long-term rate of return on plan assets 1.5 % 1.8 % 1.8 % The accumulated benefit obligation (ABO), an estimate based on the assumption if these plans were to be terminated immediately, as of December 31, 2020 and 2019 was $159.5 million and $138.6 million, respectively. The ABO and fair value of plan assets for these plans with ABO in excess of plan assets were $78.1 million and $66.3 million as of December 31, 2020 and 2019, respectively. In some foreign locations we have service award plans that are paid based upon the number of years of employment. Under these plans, the liability as of December 31, 2020 and 2019 was $4.1 million and $3.5 million, respectively, and has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets. Concentrations of Labor Subject to Collective Bargaining Agreements

13. Legal Proceedings

13. Legal Proceedings	12 Months Ended
	Dec. 31, 2020
Legal Proceedings [Abstract]
Legal Matters and Contingencies	13.    LEGAL PROCEEDINGSWe are a party to various claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.

14. Segment Reporting

14. Segment Reporting	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Segment Information	14. SEGMENT INFORMATION Bio-Rad is a multinational manufacturer and worldwide distributor of its own life science research products and clinical diagnostics products. We have two reportable segments: Life Science and Clinical Diagnostics. These reportable segments are strategic business lines that offer more than 9,000 different products and services and require different marketing strategies. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve. The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. These products are sold to university and medical school laboratories, pharmaceutical and biotechnology companies, food testing laboratories and government and industrial research facilities. The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. These products are sold to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories and insurance and forensic testing laboratories. Other Operations include our Analytical Instruments segment, and a small miscellaneous operation that was included in a prior acquisition. Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. The accounting policies of the segments are the same as those described in Significant Accounting Policies (see Note 1). Segment profit or loss includes an allocation of corporate expense based upon sales and an allocation of interest expense based upon accounts receivable and inventories. The difference between total segment allocated interest expense, depreciation and amortization, and capital expenditures and the corresponding consolidated amounts is attributable to our corporate headquarters. Segments are expected to manage only assets completely under their control. Accordingly, segment assets include primarily accounts receivable, inventories and gross machinery and equipment. Goodwill balances have been included in corporate for segment reporting purposes. Information regarding industry segments at December 31, 2020, 2019, and 2018 and for the years then ended is as follows (in millions): Life Clinical Other Segment net sales 2020 $ 1,231.8 $ 1,305.2 $ 8.6 2019 885.9 1,412.0 13.8 2018 861.7 1,411.8 15.9 Allocated interest expense 2020 $ 8.0 $ 13.8 $ 0.1 2019 7.4 15.9 0.1 2018 7.2 16.7 0.1 Depreciation and amortization 2020 $ 32.8 $ 65.1 $ 1.0 2019 29.4 71.7 0.9 2018 34.1 72.0 0.5 Segment profit (loss) 2020 $ 256.3 $ 149.1 $ (0.6) 2019 72.1 148.5 (1.5) 2018 28.7 (145.7) 0.2 Segment assets 2020 $ 607.3 $ 1,065.6 $ 9.5 2019 496.1 1,075.8 9.2 Capital expenditures 2020 $ 16.8 $ 43.6 $ 3.1 2019 16.6 58.9 0.6 Net corporate operating expense consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. The following reconciles total segment profit to consolidated income before taxes (in millions): Year Ended December 31, 2020 2019 2018 Total segment profit (loss) $ 404.8 $ 219.1 $ (116.8) Foreign currency exchange losses, net (1.8) (2.2) (2.9) Net corporate operating and other expense not allocated to segments (15.7) (12.9) (10.4) Change in fair market value of equity securities 4,495.8 2,031.0 606.2 Other income, net 24.5 26.1 36.6 Consolidated income before income taxes $ 4,907.6 $ 2,261.1 $ 512.7 The following reconciles total segment assets to consolidated total assets (in millions): December 31, 2020 2019 Total segment assets $ 1,682.4 $ 1,581.1 Cash and other current assets 1,098.2 1,233.5 Property, plant and equipment, net, and operating lease right-of-use assets, excluding segment specific balances 52.7 56.0 Goodwill, net 291.9 264.1 Other long-term assets 9,847.4 4,863.4 Total assets $ 12,972.6 $ 8,008.9 The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions): Year Ended December 31, 2020 2019 2018 Europe $ 857.7 $ 770.3 $ 792.0 Asia 546.5 505.0 495.5 United States 1,004.8 899.1 863.6 Other (primarily Canada and Latin America) 136.6 137.3 138.3 Total net sales $ 2,545.6 $ 2,311.7 $ 2,289.4 The following presents Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions): December 31, 2020 2019 Europe $ 208.6 $ 198.3 Asia 53.3 51.5 United States 454.4 468.7 Other (primarily Canada and Latin America) 12.0 12.7 Total Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes $ 728.3 $ 731.2

15. Restructuring Costs (Notes)

15. Restructuring Costs (Notes)	12 Months Ended
	Dec. 31, 2020
Restructuring Costs [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	RESTRUCTURING COSTS In December 2018, we announced the closure of a small manufacturing facility in France. Restructuring charges for the facility closure are included in our Clinical Diagnostics segment's results of operations. This restructuring plan is expected to be substantially complete by the first half of 2021. We recorded restructuring charges and adjustments related to severance and employee benefits of $(0.1) million, $(0.1) million and $3.9 million and exit costs of $0.1 million, zero and $0.2 million for the years ended December 31, 2020, 2019 and 2018, respectively. The amounts recorded were reflected in Cost of goods sold in the consolidated statements of income. The liability of $1.6 million as of December 31, 2020 consisted of $1.5 million recorded in Accrued payroll and employee benefits and $0.1 million recorded in Other current liabilities in the consolidated balance sheets. From December 2018 to December 31, 2020, total expenses were $4.0 million. The following table summarizes the activity for the facility closure restructuring reserves for severance and exit costs (in millions): 2020 2019 Balance as of January 1 $ 3.2 $ 4.1 Adjustment to expense — (0.1) Cash payments (1.8) (0.7) Foreign currency translation losses (gains) 0.2 (0.1) Balance as of December 31 $ 1.6 $ 3.2 In November 2019, we announced our strategy-driven restructuring plan. We expect that a significant portion of the net savings resulting from this restructuring plan will be repurposed in alignment with our portfolio strategy. The restructuring plan includes a workforce reduction in Europe, the United States and Canada, and is expected to be substantially complete by the first half of 2022. We recorded $(4.8) million and $25.3 million of expenses and adjustments in restructuring charges related to severance and employee benefits for the years ended December 31, 2020 and 2019, respectively. The liability of $2.8 million as of December 31, 2020 was recorded in Accrued payroll and employee benefits in the consolidated balance sheets. The amounts recorded were reflected in Cost of goods sold of $(1.9) million and $4.8 million, in Selling, general and administrative expense of $(1.7) million and $14.4 million and in Research and development expense of $(1.2) million and $6.1 million in the consolidated statements of income for the years ended December 31, 2020 and 2019, respectively. From November 2019 to December 31, 2020, total expenses were $20.5 million. The following table summarizes the activity of our European and North American reorganization restructuring reserves for severance (in millions): 2020 2019 Life Science Clinical Diagnostics Total Life Science Clinical Diagnostics Total Balance as of January 1 $ 6.2 $ 19.1 $ 25.3 $ — $ — $ — Charged to expense — — — 6.2 19.1 25.3 Adjustment to expense (0.6) (4.2) (4.8) — — — Cash payments (4.7) (13.4) (18.1) (0.4) (0.7) (1.1) Reserve transferred from prior restructuring plan — — — 0.3 0.4 0.7 Foreign currency translation losses — 0.4 0.4 0.1 0.3 0.4 Balance as of December 31 $ 0.9 $ 1.9 $ 2.8 $ 6.2 $ 19.1 $ 25.3 In June 2020, we announced a restructuring plan to consolidate certain finance and administrative activities in Europe and the United States. The restructuring plan is expected to be substantially complete by the first half of 2022. The liability of $2.7 million as of December 31, 2020 was recorded in Accrued payroll and employee benefits in the consolidated balance sheet. The amount reflected in Selling, general and administrative expense was $3.9 million for the year ended December 31, 2020. The following table summarizes the restructuring activities related to the finance and administrative reorganization (in millions): 2020 Life Science Clinical Diagnostics Total Balances as of January 1 $ — $ — $ — Charged to expense 1.5 2.3 3.8 Adjustment to expense 0.1 — 0.1 Cash payments (0.5) (0.8) (1.3) Foreign currency translation losses — 0.1 0.1 Balances as of December 31 $ 1.1 $ 1.6 $ 2.7

16. Leases (Notes)

16. Leases (Notes)	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Leases of Lessee Disclosure [Text Block]	16. LEASES For our accounting policies on leases, including l eases where we act as lessor in reagent rental agreements , see Note 1. We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 18 years, which includes our determination to exercise renewal options. The components of lease expense were as follows (in millions): Twelve Months Ended December 31, 2020 2019 Operating lease cost $ 45.4 $ 51.4 Finance lease cost: Amortization of right-to-use assets $0.6 $ 0.6 Interest on lease liabilities $0.8 0.9 Total finance lease cost $ 1.4 $ 1.5 Sublease income $ 3.0 $ 3.0 The sublease is for a building with a term that ends in 2025, with no options to extend or renew. Operating lease cost includes original reduction in the carrying amount of right-of-use assets, the impact of remeasurements, modifications, impairments and abandonments. Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not significant for the years ended December 31, 2020 and 2019. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for the years ended December 31, 2020 and 2019. Supplemental cash flow information related to leases was as follows (in millions): Twelve Months Ended December 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 44.4 $ 47.2 Operating cash flows from finance leases $ 0.6 $ 0.9 Financing cash flows from finance leases $ 0.8 $ 0.6 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 16.1 $ 28.7 Finance leases $ 0.4 $ 0.2 Supplemental balance sheet information related to leases was as follows (in millions): December 31, 2020 2019 Operating Leases Operating lease right-of-use assets $ 202.1 $ 201.9 Current operating lease liabilities $ 36.5 $ 35.4 Operating lease liabilities 175.1 176.0 Total operating lease liabilities $ 211.6 $ 211.4 Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities. December 31, 2020 2019 Finance Leases Property, plant and equipment, gross $ 12.2 $ 11.4 Less: accumulated depreciation and amortization (5.0) (4.2) Property, plant and equipment, net $ 7.2 $ 7.2 Current maturities of long-term debt and notes payable $ 0.5 $ 0.5 Long-term debt, net of current maturities 11.0 11.2 Total finance lease liabilities $ 11.5 $ 11.7 December 31, 2020 2019 Weighted Average Remaining Lease Term Operating leases - in years 8 9 Finance leases - in years 16 18 Weighted Average Discount Rate Operating leases 3.9 % 4.2 % Finance leases 6.2 % 6.5 % Maturities of lease liabilities were as follows (in millions): Year Ending December 31, Operating Leases Finance Leases 2021 $ 43.6 $ 1.3 2022 36.5 1.2 2023 31.9 1.2 2024 27.2 1.2 2025 23.2 1.1 Thereafter 90.5 14.0 Total lease payments 252.9 20.0 Less imputed interest (41.3) (8.5) Total $ 211.6 $ 11.5 The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles and other equipment with shorter terms and higher-turn over. As of December 31, 2020, operating leases that have not commenced are not material. Operating Leases Under ASC 840, Leases Rents and Leases Rental expense under operating leases was $47.4 million in 2018. Leases were principally for facilities and automobiles.

17. Quarterly Financial Data

17. Quarterly Financial Data	12 Months Ended
	Dec. 31, 2020
Quarterly Financial Data [Abstract]
Quarterly Financial Data [Text Block]	17. QUARTERLY FINANCIAL DATA (UNAUDITED - see accompanying accountants' report) Summarized quarterly financial data for the years ended December 31, 2020 and 2019 are as follows (in millions, except per share data): First Second Third Fourth 2020 Net sales $ 571.6 $ 536.9 $ 647.3 $ 789.8 Gross profit $ 317.4 $ 293.0 $ 367.3 $ 460.1 Net income $ 685.9 $ 966.4 $ 1,314.8 $ 839.2 Basic earnings per share $ 22.97 $ 32.59 $ 44.24 $ 28.13 Diluted earnings per share $ 22.72 $ 32.15 $ 43.64 $ 27.81 2019 Net sales $ 554.0 $ 572.6 $ 560.6 $ 624.5 Gross profit $ 311.8 $ 307.8 $ 307.0 $ 330.4 Net income (loss) $ 865.2 $ 598.8 $ (258.8) $ 553.5 Basic earnings (loss) per share $ 29.03 $ 20.08 $ (8.68) $ 18.50 Diluted earnings (loss) per share $ 28.74 $ 19.86 $ (8.68) $ 18.31

18. Subsequent Event (Notes)

18. Subsequent Event (Notes)	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events [Text Block]	SUBSEQUENT EVENT On February 3, 2021, we initiated a strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacts our operations in Europe and includes the elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing operations from Europe to Asia. The restructuring plan is expected to eliminate a total of approximately 530 positions and the subsequent creation of a total of approximately 325 new positions. We anticipate the restructuring plan will be implemented in phases and is expected to be substantially completed by the end of fiscal year 2022. We estimate that as a result of this restructuring plan we will incur between approximately $125 million and $130 million in total cost, which we anticipate will consist of: (i) approximately $86 million cash expenditures in the form of one-time termination benefits to the affected employees, including cash severance payments, healthcare benefits, and related transition assistance; (ii) approximately $19 million in capital expenditures associated with the restructuring plan; and (iii) between approximately $20 million and $25 million in one-time transition costs, including employee transition costs, supply chain costs and regulatory costs. We anticipate that we will record approximately $80 million to $90 million of the charges related to this restructuring plan in the first quarter of fiscal year 2021. The amounts are preliminary estimates based on the information currently available to management. It is possible that additional charges and future cash payments could occur in relation to the restructuring actions.

1. Significant Accounting Pol_2

1. Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash. Cash equivalents are stated at cost, which approximates fair value.
Short-term Restricted Investments	Short-term Restricted Investments Short-term restricted investments of $5.6 million at both December 31, 2020 and 2019 represent a money market fund that is provided as collateral to secure worker's compensation and general liability insurance.
Available-for-sale Investments	Available-for-Sale Investments Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities and U.S. government sponsored agencies. Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date. Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations. Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data. Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect. On January 1, 2020, we adopted Accounting Standards Update (ASU) 2016-13 described below under "Recent Accounting Pronouncements Adopted." In accordance with the adopted guidance, we replaced the incurred loss approach with an expected loss model for instruments measured at amortized cost and we record allowances for available-for-sale debt securities rather than to reduce the carrying amount for other-than-temporary impairment as was followed under the other-than-temporary impairment model prior to January 1, 2020. Realized gains and losses and other-than-temporary impairments on investments are included in Other income and expense, net (see Note 10).
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable. Cash and cash equivalents and investments are placed with various highly rated major financial institutions located in different geographic regions. The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements. We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions. In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end. Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas. We manage our accounts receivable credit risk through ongoing credit evaluation of our customers' financial conditions. We generally do not require collateral from our customers.
Accounts Receivable	Accounts Receivable and Allowance for Doubtful Accounts We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. On January 1, 2020 we adopted ASU 2016-13, "Measurement of Credit Losses on Financial Instruments" as described below and review our exposure to accounts receivable and reserve for amounts if collectability is no longer reasonably assured based on an assessment of various factors including historical loss rates and expectations of forward-looking loss estimates. Prior to January 1, 2020, the allowance for doubtful accounts was determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers' country or industry, historical losses and our customers' credit-worthiness. Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance. Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of the customer. Changes in our allowance for doubtful accounts were as follows (in millions): December 31, 2020 2019 2018 Beginning balance $ 20.2 $ 26.7 $ 25.5 Provision for expected credit losses (2020), bad debt (reversal) expense (2019 and 2018) 1.2 (1.2) 3.9 Write-offs charged against the allowance (1.6) (6.6) (2.7) Recoveries collected — 1.3 — Ending balance $ 19.8 $ 20.2 $ 26.7
Inventory	Inventory Inventories are valued at the lower of cost and net realizable value and include material, labor and overhead costs. Cost is determined using standard costs, which approximate actual costs, and are relieved from inventory on a first-in, first-out or average cost basis. We classify our inventories based on our historical and anticipated levels of sales; any inventory in excess of its normal operating cycle (1 – 3 years depending on our product line) is classified as long-term on our consolidated balance sheets. The long-term inventory was immaterial as of December 31, 2020 and 2019.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Additions and improvements are capitalized, and maintenance and repairs are expensed as incurred. Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets. The estimated useful lives of property, plant and equipment are generally as follows: buildings, 10-50 years; leasehold improvements, the life of the improvements or the term of the lease, whichever is shorter; reagent rental equipment, 1-5 years; and equipment, 3-12 years. When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are relieved from the accounts and the net gain or loss is included in operating expenses.
Leases	Leases We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our Consolidated Balance Sheets. Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities in our Consolidated Balance Sheets.
Lessor, Leases	Where we act as lessor in our reagent rental arrangements, we allocate the consideration in the contract to the separate lease components and non-lease components. After allocation, the amount of variable payments allocated to lease components will be recognized as income under the lease accounting standard ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Such reagent rental arrangements are more fully described below under the caption "Reagent Rental Agreements."
Goodwill	Impairment of Goodwill Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. We conduct a goodwill impairment analysis annually in the fourth quarter or more frequently if indicators of impairment exist or if a decision is made to sell or exit a business. Significant judgments are involved in determining if an indicator of impairment has occurred. Such indicators may include deterioration in general economic conditions, negative developments in equity and credit markets, adverse changes in the markets in which an entity operates, increases in input costs that have a negative effect on earnings and cash flows, or a trend of negative or declining cash flows over multiple periods, among others. The fair value that could be realized in an actual transaction may differ from that used to evaluate the impairment of goodwill. In reviewing goodwill for impairment, we have the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not (greater than 50%) that the estimated fair value of a reporting unit is less than its carrying amount. For the year ended December 31, 2020, we elected to perform a qualitative assessment and determined that an impairment was not more likely than not and no further analysis was required. We also may elect not to perform the qualitative assessment and, instead, proceed directly to the quantitative impairment test. The ultimate outcome of the goodwill impairment review for a reporting unit should be the same whether we choose to perform the qualitative assessment or proceed directly to the quantitative impairment test.
Long-Lived Assets	Impairment of Long-Lived Assets We review long-lived assets, such as property, plant and equipment, and finite-lived intangible assets, for impairment whenever events indicate that the carrying amounts might not be recoverable. Recoverability of property, plant and equipment, and other finite-lived intangible asset is measured by comparing the projected undiscounted net cash flows associated with those assets to their carrying values. If an asset is considered impaired, it is written down to its fair value, which is determined based on the asset's projected discounted cash flows or appraised value, depending on the nature of the asset. For purposes of recognition of impairment for assets held for use, we group assets and liabilities at the lowest level for which cash flows are separately identifiable. For the year ended December 31, 2018, we impaired some finite-lived intangible assets in the amount of $10.5 million that were included in our Life Science segment's results of operations. There were no impairments of finite-lived intangible assets for the years ended December 31, 2020 and 2019.
Income Taxes	Income Taxes We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities reflect the tax effects of net operating losses, tax credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which such temporary differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. We record deferred tax assets to the extent we believe these assets will more likely than not be realized. In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. When we establish or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement. The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes. On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities. In 2017, we recorded an income tax benefit of $70 million related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. We completed our accounting for the Tax Act under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) in 2018, which resulted in an additional income tax benefit of $49 million.
Revenue Recognition	Revenue Recognition We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recognized until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to customer specifications, which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control in relation to the equipment has occurred at that point as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon customer acceptance because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. In the fourth quarter of fiscal year 2020, we received $35.3 million in court awarded damages related to an intellectual property litigation for sales of products infringing on our patents during 2015 to 2018. Of the total amount, we recognized $32.3 million as revenue upon receipt of the damages based on the estimated stand-alone royalty rate associated with the infringed patents.
Revenue Recognition, Leases	Reagent Rental Agreements Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at lease commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. For purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the Company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Generally these arrangements do not contain an option for the lessee to purchase the underlying asset. We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Upon our adoption of ASC 842 in 2019, the maintenance services, along with the reagents, are now allocated to the non-lease elements and will be recognized as income in accordance with ASC 606. This change is in accordance with the requirements of ASC 842, and has resulted in a decrease in the amount of rental income and a corresponding increase in the amount of maintenance service revenue that is included in Net sales in our consolidated statements of income. Generally, the terms of the arrangements result in the transfer of control for reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments. Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate an immaterial amount of lease income. Our reported lease income is primarily variable in nature and is recognized upon delivery or as the reagents are consumed by the customer. Revenue allocated to the lease elements of these reagent rental arrangements represented approximately 3% of total revenue at both December 31, 2020 and 2019, respectively, and 5% at December 31, 2018, and are included as part of the Net sales in our consolidated statements of income. Contract costs: As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our consolidated statements of income. Disaggregation of Revenue:
Revenue Recognition, Deferred Revenue	Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements. The deferred revenue balance at December 31, 2020 and December 31, 2019 was $60.0 million and $45.8 million, respectively. The short-term deferred revenue balance at December 31, 2020 and December 31, 2019 was $42.5 million and $33.7 million, respectively.
Warranty	We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our consolidated statements of income. Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the Consolidated Balance Sheets. Change in our warranty liability were as follows (in millions): 2020 2019 2018 January 1 $ 9.0 $ 10.1 $ 18.7 Provision for warranty 9.4 9.9 25.5 Actual warranty costs (8.6) (11.0) (34.1) December 31 $ 9.8 $ 9.0 $ 10.1
Shipping and Handling	Shipping and Handling We classify all freight costs billed to customers as Net sales. Related freight costs are recognized upon transfer of control of the promised products to customers as a fulfillment cost and included in Cost of goods sold.
Research and Development Expense	Research and DevelopmentAll research and development costs are expensed as incurred. Types of expense incurred in research and development include materials and supplies, employee compensation, consulting and third-party services, depreciation, facility costs and information technology.
Foreign Currency	Foreign Currency Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period. Income statement items are translated at average exchange rates for the period. The resulting translation adjustments are recorded as a separate component of stockholders’ equity. Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income. Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction.
Forward Foreign Exchange Contracts	Forward Foreign Exchange ContractsAs part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.
Share-based Compensation Plans	Share-Based Compensation Plans Share-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value. We recognize these compensation costs over the requisite service period of the award, which is generally the vesting term of the share-based payment awards. Forfeitures are recognized as they occur. These plans are described more fully in Note 9.
Earnings Per Share	Earnings Per Share Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings per share calculation if the effect of including such securities would be anti-dilutive. The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands): Year Ended December 31, 2020 2019 2018 Basic weighted average shares outstanding 29,768 29,843 29,836 Effect of potentially dilutive stock options and restricted stock awards 392 341 392 Diluted weighted average common shares 30,160 30,184 30,228 Anti-dilutive stock options and restricted stock awards excluded from the computation of diluted EPS 44 98 84
Fair Value of Financial Instruments	Fair Value of Financial Instruments For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value. The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value. The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3).
New Accounting Pronouncements	Recent Accounting Pronouncements Adopted In March 2020, the FASB issued ASU No. 2020-04, "Facilitation of the Effects of Reference Rate Reform on Financial Reporting (Topic 848)." The ASU provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate (e.g., LIBOR) reform if certain criteria are met, for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The ASU is effective as of March 12, 2020 through December 31, 2022. We will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. The ASU is currently not expected to have a material impact on our consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements," which aims to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing fair value measurement disclosures. We adopted this standard effective January 1, 2020, which did not have a material impact on our consolidated financial statements. In August 2018, the FASB issued ASU 2018-14, "Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." ASU 2018-14 eliminates and adds certain disclosures for defined benefit plans. ASU 2018-14 was effective for fiscal years ending after December 15, 2020. We adopted the standard using a retrospective approach, which did not have a material impact to our disclosures for defined benefit plans. In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 replaces the incurred loss approach with an expected loss model for instruments measured at amortized cost and requires entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount as done under the former other-than-temporary impairment model. We adopted ASU 2016-13 as of January 1, 2020 using the cumulative effect transition method. We have evaluated our impacted instruments for credit quality indicators, and have determined that there is no cumulative effect transition adjustment to retained earnings as of our adoption date. ASU 2016-13 had an insignificant impact to our consolidated financial statements for 2020. See also Note 3, Fair Value Measurements, and the section above under the caption “Accounts Receivable and Allowance for Doubtful Accounts.” In February 2016, the FASB issued ASU 2016-02, "Leases," and related accounting standard updates, which requires, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures are enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. We adopted ASU 2016-02 on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. The practical expedients elected in transition included, among other items, for leases that existed prior to January 1, 2019, not reassessing whether any contracts are or contain embedded leases, not reassessing the classification of existing leases, and not reassessing whether previously capitalized initial direct costs qualify for capitalization. Where we act as a lessee, the adoption of the standard resulted in material additions to the balance sheet for right-of-use assets and the associated liabilities. See Note 16, Leases. Where we act as a lessee, we also elected not to separate lease and non-lease components. Where we act as a lessor in reagent rental arrangements, there was an insignificant impact to our Consolidated Financial Statements, which is more fully described above under the caption "Reagent Rental Agreements." Recent Accounting Pronouncements to be Adopted In January 2020, the FASB issued ASU 2020-01, "Clarifying the Interactions between Topic 321 Investments—Equity Securities, Topic 323 Investments—Equity Method and Joint Ventures, and Topic 815 Derivatives and Hedging." ASU 2020-01 clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under Topic 323 for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. ASU 2020-01 also clarifies that, when determining the accounting for certain forward contracts and purchased options a company should not consider, whether upon settlement or exercise, if the underlying securities would be accounted for under the equity method or fair value option. ASU 2020-01 was effective for fiscal years beginning after December 15, 2020. We do not expect ASU 2020-01 to have a material impact to our consolidated financial statements. In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes," which eliminates certain exceptions within ASC 740, Income Taxes , and clarifies other aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 was effective for fiscal years beginning after December 15, 2020, with any adjustments reflected as of January 1, 2021 . The adoption of ASU 2019-12 is not expected to have a material impact on the consolidated financial statements.
Goodwill and Intangible Assets, Intangible Assets, Policy	Intangible Assets Our intangible assets principally include goodwill, acquired technology / know how, license, tradenames and customer relationships. Intangible assets with finite lives, which include acquired technology / know how, tradenames, licenses and customer relationships, are carried at cost and amortized using the straight-line method over their useful lives ranging from 3 to 20 years. Intangible assets with indefinite lives, which include only goodwill, are recorded at cost and evaluated at least annually for impairment.
Equity Method Investments	Equity Investments Investments in publicly traded companies in which we do not have the ability to exercise significant influence are reported at fair value, with unrealized gains and losses reported as a component of change in fair market value of equity securities in our consolidated statements of income. Companies in which we do not have a controlling financial interest, but over which we have significant influence, are accounted for using the equity method. Our share of the after-tax earnings of equity method investees is included in other income, net in our consolidated statements of income . Investments in privately held companies in which we do not have the ability to exercise significant influence are accounted for using the cost method with adjustments for observable changes in price or impairments (see Note 3).

1. Significant Accounting Pol_3

1. Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of Product Warranty Liability	Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the Consolidated Balance Sheets. Change in our warranty liability were as follows (in millions): 2020 2019 2018 January 1 $ 9.0 $ 10.1 $ 18.7 Provision for warranty 9.4 9.9 25.5 Actual warranty costs (8.6) (11.0) (34.1) December 31 $ 9.8 $ 9.0 $ 10.1
Schedule of Weighted Average Number of Shares	The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands): Year Ended December 31, 2020 2019 2018 Basic weighted average shares outstanding 29,768 29,843 29,836 Effect of potentially dilutive stock options and restricted stock awards 392 341 392 Diluted weighted average common shares 30,160 30,184 30,228 Anti-dilutive stock options and restricted stock awards excluded from the computation of diluted EPS 44 98 84
Accounts Receivable, Allowance for Credit Loss	Changes in our allowance for doubtful accounts were as follows (in millions): December 31, 2020 2019 2018 Beginning balance $ 20.2 $ 26.7 $ 25.5 Provision for expected credit losses (2020), bad debt (reversal) expense (2019 and 2018) 1.2 (1.2) 3.9 Write-offs charged against the allowance (1.6) (6.6) (2.7) Recoveries collected — 1.3 — Ending balance $ 19.8 $ 20.2 $ 26.7

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
	Jun. 30, 2020
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition	The fair value of consideration transferred for the Celsee acquisition consists of the following (in millions): Purchase price (cash) $ 99.2 Fair value of contingent consideration (earn-out) 0.1 Fair value of total consideration transferred $ 99.3
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the final fair values of the assets acquired and liabilities assumed at the Acquisition Date (in millions): Fair Value Cash and cash equivalents $ 0.6 Intangible assets 79.9 Deferred tax assets 8.4 Deferred tax liabilities (19.7) Other identifiable assets acquired, net 0.3 Net identifiable assets acquired 69.5 Goodwill 29.8 Net assets acquired $ 99.3
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination	The following table summarizes the final fair values and estimated useful lives of the components of identifiable intangible assets acquired as of the Acquisition Date (in millions): Fair Value Estimated Useful Life (years) Developed product technology $ 70.3 18.9 Customer relationships 3.6 4.0 Covenants not to compete 1.4 3.0 In-process research and development 4.6 Total identifiable intangible assets acquired $ 79.9

3. Fair Value Measurements (Tab

3. Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a reconciliation of the Level 3 contingent consideration liabilities measured at estimated fair value (in millions): December 31, 2019 $ 4.9 Analytical flow cytometer platform: Payment of sales milestone (3.3) Net decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense (1.0) Foreign distributor earn-outs: Change in estimated fair value of contingent consideration included in Selling, general and administrative expense — Celsee, Inc.: Fair value of contingent consideration 0.1 December 31, 2020 $ 0.7
Debt Securities, Available-for-sale [Table Text Block]	Available-for-sale investments consist of the following (in millions): December 31, 2020 Amortized Unrealized Unrealized Allowances for Credit Losses Estimated Short-term investments: Corporate debt securities $ 130.5 $ 2.7 $ — — $ 133.2 Municipal obligations 15.0 0.2 — — 15.2 Asset-backed securities 35.8 0.3 — — 36.1 U.S. government sponsored agencies 74.7 2.2 — — 76.9 Foreign government obligations 4.0 — — — 4.0 Other foreign obligations 2.1 — — — 2.1 262.1 5.4 — — 267.5 Long-term investments: Asset-backed securities 0.1 — — — 0.1 0.1 — — — 0.1 Total $ 262.2 $ 5.4 $ — $ — $ 267.6	Available-for-sale investments consist of the following (in millions): December 31, 2019 Amortized Unrealized Unrealized Estimated Short-term investments: Corporate debt securities $ 203.2 $ 1.4 $ (0.1) $ 204.5 Municipal obligations 11.5 0.1 — 11.6 Asset-backed securities 72.7 0.2 (0.1) 72.8 U.S. government sponsored agencies 105.6 0.7 (0.2) 106.1 Foreign government obligations 4.7 — — 4.7 Other foreign obligations 3.1 — — 3.1 400.8 2.4 (0.4) 402.8 Long-term investments: Asset-backed securities 0.1 — — 0.1 0.1 — — 0.1 Total $ 400.9 $ 2.4 $ (0.4) $ 402.9
Summary of amortized cost and estimated fair value of debt securities by contractual maturity date	The following is a summary of the amortized cost and estimated fair value of our debt securities at December 31, 2020 by contractual maturity date (in millions): Amortized Estimated Fair Mature in less than one year $ 130.9 $ 131.5 Mature in one to five years 88.1 90.5 Mature in more than five years 43.2 45.6 Total $ 262.2 $ 267.6
Summary of investments with gross unrealized losses and the associated fair value	The following is a summary of investments with gross unrealized losses and the associated fair value (in millions): There were no significant unrealized losses as of December 31, 2020 in either the less than or greater than 12 month categories. Gross unrealized losses and associated fair value (in millions) as of December 31, 2019 were: December 31, 2019 Less than 12 months Greater than 12 months Total Description of securities: Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 46.5 $ 0.1 $ 2.1 $ — $ 48.6 $ 0.1 Asset-backed securities 17.9 — 7.0 0.1 24.9 0.1 U.S. government sponsored agencies 27.5 0.2 10.8 — 38.3 0.2 Total $ 91.9 $ 0.3 $ 19.9 $ 0.1 $ 111.8 $ 0.4
Schedule of Derivative Instruments [Table Text Block]	The following is a summary of our forward foreign currency exchange contracts (in millions): December 31, 2020 Contracts maturing in January through March 2021 to sell foreign currency: Notional value $ 125.3 Unrealized loss $ (0.4) Contracts maturing in January through March 2021 to purchase foreign currency: Notional value $ 301.6 Unrealized gain $ 0.4
Estimated fair value of financial instruments	The estimated fair value of our long-term debt and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions): December 31, 2020 December 31, 2019 Carrying Estimated Fair Value Hierarchy Level Carrying Estimated Fair Value Hierarchy Level Total current maturities long-term debt, excluding leases $ — $ — N/A $ 424.4 $ 435.5 2
Fair Value Measurements, Recurring and Nonrecurring	Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2020 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 41.7 $ — $ 41.7 Time deposits 17.6 10.0 — 27.6 Asset-backed securities — 0.9 — 0.9 U.S. government sponsored agencies — 2.5 — 2.5 Money market funds 60.1 — — 60.1 Total cash equivalents (a) 77.7 55.1 — 132.8 Restricted investments (b) 6.7 — — 6.7 Equity Securities (c) 9,582.4 — — 9,582.4 Available-for-sale investments: Corporate debt securities — 133.2 — 133.2 U.S. government sponsored agencies — 76.9 — 76.9 Foreign government obligations — 4.0 — 4.0 Other foreign obligations — 2.1 — 2.1 Municipal obligations — 15.2 — 15.2 Asset-backed securities — 36.2 — 36.2 Total available-for-sale investments (d) — 267.6 — 267.6 Forward foreign exchange contracts (e) — 1.0 — 1.0 Total financial assets carried at fair value $ 9,666.8 $ 323.7 $ — $ 9,990.5 Financial liabilities carried at fair value: Forward foreign exchange contracts (f) $ — $ 1.0 $ — $ 1.0 Contingent consideration (g) — — 0.7 0.7 Total financial liabilities carried at fair value $ — $ 1.0 $ 0.7 $ 1.7 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2019 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 42.9 $ — $ 42.9 Time deposits 31.2 10.0 — 41.2 Asset-backed securities — 0.1 — 0.1 Money market funds 69.9 — — 69.9 Total cash equivalents (a) 101.1 53.0 — 154.1 Restricted investments (b) 5.6 — — 5.6 Equity securities (c) 4,664.4 — — 4,664.4 Available-for-sale investments: Corporate debt securities — 204.5 — 204.5 U.S. government sponsored agencies — 106.1 — 106.1 Foreign government obligations — 4.7 — 4.7 Other foreign obligations — 3.1 — 3.1 Municipal obligations — 11.6 — 11.6 Asset-backed securities — 72.9 — 72.9 Total available-for-sale investments (d) — 402.9 — 402.9 Forward foreign exchange contracts (e) — 0.9 — 0.9 Total financial assets carried at fair value $ 4,771.1 $ 456.8 $ — $ 5,227.9 Financial liabilities carried at fair value: Forward foreign exchange contracts (f) $ — $ 1.0 $ — $ 1.0 Contingent consideration (g) — — 4.9 4.9 Total financial liabilities carried at fair value $ — $ 1.0 $ 4.9 $ 5.9 (a) Cash equivalents are included in Cash and cash equivalents in the consolidated balance sheets. (b) Restricted investments are included in the following accounts in the consolidated balance sheets (in millions): December 31, 2020 December 31, 2019 Restricted investments $ 5.6 $ 5.6 Other investments 1.1 — Total $ 6.7 $ 5.6 (c) Equity securities are included in the following accounts in the consolidated balance sheets (in millions): December 31, 2020 December 31, 2019 Short-term investments $ 61.4 $ 51.0 Other investments 9,521.0 4,613.4 Total $ 9,582.4 $ 4,664.4 The change in fair market value on our equity securities for the year ended December 31, 2020 was $4,495.8 million gain, which was primarily due to our investment in Sartorius AG and is recorded in our consolidated statements of income. As of December 31, 2020, we own 12,987,900 ordinary voting shares and 9,588,908 preferenc e shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We did not purchase any incremental shares for the years ended December 31, 2020 and 2019. We own approximately 37% of the ordinary outstanding voting shares (excluding treasury shares) and 28% of the preference shares of Sartorius as of December 31, 2020. The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius' board of directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. (d) Available-for-sale investments are included in the following accounts in the consolidated balance sheets (in millions): December 31, December 31, 2019 Short-term investments $ 267.5 $ 402.8 Other investments 0.1 0.1 Total $ 267.6 $ 402.9 (e) Forward foreign exchange contracts in an asset position are included in other current assets in the consolidated balance sheets. (f) Forward foreign exchange contracts in a liability position are included in other current liabilities in the consolidated balance sheets. (g) Contingent consideration liabilities are included in the following accounts in the consolidated balance sheets (in millions): December 31, 2020 December 31, 2019 Other current liabilities $ 0.6 $ 3.3 Other long-term liabilities 0.1 1.6 Total $ 0.7 $ 4.9

4. Intangible Assets, Goodwil_2

4. Intangible Assets, Goodwill and Other (Tables)	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Changes to goodwill by segment	Changes to goodwill by segment were as follows (in millions): 2020 2019 Life Clinical Total Life Clinical Total Balances as of January 1: Goodwill $ 250.1 $ 349.2 $ 599.3 $ 234.5 $ 320.5 $ 555.0 Accumulated impairment losses and write-offs (41.8) (293.4) (335.2) (41.8) (293.4) (335.2) Goodwill, net 208.3 55.8 264.1 192.7 27.1 219.8 Acquisitions (see Note 2) 29.8 — 29.8 15.6 28.7 44.3 Other adjustments (see Note 2) (2.0) — (2.0) — — — Period increase, net 27.8 — 27.8 15.6 28.7 44.3 Balances as of December 31: Goodwill 277.9 349.2 627.1 250.1 349.2 599.3 Accumulated impairment losses and write-offs (41.8) (293.4) (335.2) (41.8) (293.4) (335.2) Goodwill, net $ 236.1 $ 55.8 $ 291.9 $ 208.3 $ 55.8 $ 264.1
Schedule of Finite-Lived Intangible Assets by Major-Class	Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions): December 31, 2020 Weighted-Average Amortization Period (years) Purchase Accumulated Net Customer relationships/lists 5.51 $ 116.6 $ (87.2) $ 29.4 Know how 4.75 196.6 (175.4) 21.2 Developed product technology 14.00 218.1 (107.1) 111.0 Licenses 7.73 65.6 (37.4) 28.2 Tradenames 7.82 6.6 (4.2) 2.4 Covenants not to compete 3.87 4.5 (2.0) 2.5 Other — 0.1 (0.1) — Total definite-lived intangible assets 608.1 (413.4) 194.7 In-process research and development 4.8 — 4.8 Total purchased intangible assets $ 612.9 $ (413.4) $ 199.5 December 31, 2019 Weighted-Average Amortization Period (years) Purchase Accumulated Net Customer relationships/lists 6.36 $ 107.2 $ (74.3) $ 32.9 Know how 5.71 188.5 (162.6) 25.9 Developed product technology 8.31 144.2 (93.9) 50.3 Licenses 8.74 76.0 (44.4) 31.6 Tradenames 8.50 6.4 (3.6) 2.8 Covenants not to compete 6.01 3.2 (1.4) 1.8 Other — 0.1 (0.1) — Total definite-lived intangible assets 525.6 (380.3) 145.3 In-process research and development 0.2 — 0.2 Total purchased intangible assets $ 525.8 $ (380.3) $ 145.5

5. Notes Payable and Long-Ter_2

5. Notes Payable and Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Principal components of long-term debt [Table Text Block]	The principal components of long-term debt are as follows (in millions): December 31, 2020 December 31, 2019 4.875% Senior Notes due 2020, net of discount $ — $ 425.0 Less unamortized discount and debt issuance costs — (0.6) Long-term debt less unamortized discount and debt issuance costs — 424.4 Finance leases and other debt 14.1 15.4 14.1 439.8 Less current maturities (1.8) (426.2) Long-term debt $ 12.3 $ 13.6

6. Income Taxes (Tables)

6. Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
U.S. and international components of income before taxes [Table Text Block]	The U.S. and international components of income before taxes are as follows (in millions): Year Ended December 31, 2020 2019 2018 U.S. $ 2,339.7 $ 1,034.0 $ 363.4 International 2,567.9 1,227.1 149.3 Income before taxes $ 4,907.6 $ 2,261.1 $ 512.7
Provision for income taxes [Table Text Block]	The provision for income taxes consists of the following (in millions): Year Ended December 31, 2020 2019 2018 Current tax expense: U.S. Federal $ 69.9 $ 13.0 $ 8.8 State 12.0 4.4 2.2 International 22.3 23.5 30.5 Current tax expense 104.2 40.9 41.5 Deferred tax expense: U.S. Federal 893.5 409.7 114.0 State 54.0 24.4 6.6 International 31.5 16.1 0.3 Deferred tax expense 979.0 450.2 120.9 Non-current tax expense (benefit) 18.2 11.3 (15.4) Provision for income taxes $ 1,101.4 $ 502.4 $ 147.0
Reconcilation of effective tax rate on inocme before taxes and statutory rate [Table Text Block]	The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows: Year Ended December 31, 2020 2019 2018 U. S. statutory tax rate 21.0 % 21.0 % 21.0 % Impact of foreign operations (9.9) (9.7) (4.1) Goodwill impairment — — 5.6 U.S. taxation of foreign income 10.2 10.3 15.5 U.S. tax reform — — (9.6) State taxes 1.1 1.0 1.7 Other — (0.4) (1.4) Provision for income taxes 22.4 % 22.2 % 28.7 %
Significant components of deferred tax assets and liabilities [Table Text Block]	Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of deferred tax assets and liabilities are as follows (in millions): December 31, 2020 2019 Deferred tax assets: Bad debt, inventory and warranty accruals $ 29.6 $ 23.9 Other post-employment benefits, vacation and other reserves 29.8 23.0 Tax credit and net operating loss carryforwards 93.5 83.7 Lease obligations 49.3 48.6 Other 44.8 26.0 Total gross deferred tax assets 247.0 205.2 Valuation allowance (44.6) (67.2) Total deferred tax assets 202.4 138.0 Deferred tax liabilities: Property and equipment 37.0 38.4 Lease assets 46.8 46.4 Investments and intangible assets 2,143.4 1,001.4 Total deferred tax liabilities 2,227.2 1,086.2 Net deferred tax liabilities $ (2,024.8) $ (948.2)
Tabular reconcilation of total amounts of unrecognized tax benefits [Table Text Block]	The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions): 2020 2019 2018 Unrecognized tax benefits – January 1 $ 39.2 $ 29.8 $ 54.9 Additions to tax positions related to prior years 14.0 7.6 0.6 Reductions to tax positions related to prior years (1.5) (0.7) (20.2) Additions to tax positions related to the current year 3.4 3.0 4.6 Settlements — — (6.8) Lapse of statute of limitations (0.6) (0.4) (1.1) Currency translation 1.3 (0.1) (2.2) Unrecognized tax benefits – December 31 $ 55.8 $ 39.2 $ 29.8
Summary of Valuation Allowance	The valuation allowance for deferred tax assets is as follows (in millions): December 31, 2020 2019 2018 Beginning balance $ 67.2 $ 70.8 $ 66.4 Additions charged to expenses — — 4.4 Deductions from reserves (22.6) (3.6) — Ending balance $ 44.6 $ 67.2 $ 70.8

7. Stockholders' Equity (Tables

7. Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Schedule of Stock by Class [Table Text Block]	Changes to Bio-Rad's issued common stock shares are as follows (in thousands): Class A Shares Class B Shares Balance at January 1, 2018 24,679 5,108 Class B to Class A conversions 30 (30) Issuance of common stock 175 18 Balance at December 31, 2018 24,884 5,096 Class B to Class A conversions 24 (24) Issuance of common stock 58 18 Balance at December 31, 2019 24,966 5,090 Class B to Class A conversions 32 (32) Issuance of common stock 75 18 Balance at December 31, 2020 25,073 5,076
Class of Treasury Stock [Table Text Block]	The share repurchase activity under the share repurchase program through open market transactions for the years ended December 31, 2020, 2019 and 2018 are summarized as follows: Number of Shares Purchased Weighted-Average Price per Share Total Shares Repurchased To Date Remaining Authorized Value November 1, 2018 - November 30, 2018 178,911 $ 273.39 193,150 $ 201.1 May 1, 2019 - May 31, 2019 25,421 $ 291.70 218,571 $ 193.7 June 1, 2019 - June 30, 2019 25,977 $ 292.01 244,548 $ 186.1 August 1, 2019 - August 31, 2019 14,745 $ 339.05 259,293 $ 181.1 November 1, 2019 - November 30, 2019 22,343 $ 358.04 281,636 $ 173.1 March 1, 2020 - March 31, 2020 291,941 $ 342.55 573,577 $ 73.1

8. Accumulated Other Comprehe_2

8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables)	12 Months Ended
	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Accumulated other comprehensive income (loss) included in our consolidated balance sheets and consolidated statements of changes in stockholders' equity consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains (losses) on available-for-sale investments Total Accumulated other comprehensive income (loss) Balances as of January 1, 2019 $ (35.5) $ (14.8) $ 3.3 $ (47.0) Other comprehensive (loss) income, before reclassifications (36.5) (10.0) 4.8 (41.7) Amounts reclassified from Accumulated other comprehensive income — 1.5 (0.4) 1.1 Income tax effects (0.4) 1.1 (0.5) 0.2 Other comprehensive income (loss), net of income taxes (36.9) (7.4) 3.9 (40.4) Balances as of December 31, 2019 $ (72.4) $ (22.2) $ 7.2 $ (87.4) Other comprehensive income (loss), before reclassifications 371.9 (5.3) 4.0 370.6 Amounts reclassified from Accumulated other comprehensive income — 0.3 (0.6) (0.3) Income tax effects (0.9) 1.2 (0.8) (0.5) Other comprehensive income (loss), net of income taxes 371.0 (3.8) 2.6 369.8 Balances as of December 31, 2020 $ 298.6 $ (26.0) $ 9.8 $ 282.4

8. Accumulated Other Comprehe_3

8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)	12 Months Ended
	Dec. 31, 2020
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	All amounts reclassified out of accumulated other comprehensive income were reclassified into other income, net in the consolidated statements of income. Reclassification adjustments are calculated using the specific identification method.

9. Share-based Compensation (Ta

9. Share-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement, Noncash Expense [Abstract]
Stock Options Activity	The following table summarizes stock option activity: Shares Weighted- Weighted- Aggregate Outstanding, December 31, 2019 344,522 $ 162.23 Granted 22,527 $ 524.30 Exercised (66,085) $ 112.96 Forfeited (15,841) $ 269.64 Outstanding, December 31, 2020 285,123 $ 196.29 4.64 $ 110.2 Unvested, December 31, 2020 73,126 $ 364.07 8.35 $ 16.0 Exercisable, December 31, 2020 211,997 $ 138.42 3.36 $ 94.2
Stock Options Valuation Assumptions	The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions: Year Ended December 31, 2020 2019 2018 Expected volatility 27 % 22 % 22 % Risk-free interest rate 0.31 % 1.69 % 2.85 % Expected life (in years) 7.4 7.5 7.6 Expected dividend — — — Weighted-average fair value of options granted $ 153.32 $ 93.96 $ 105.94
Resticted Stock Activity	The following table summarizes restricted stock unit activity: Weighted- Weighted-Average Aggregate Outstanding, December 31, 2019 469,942 $ 279.14 Granted 112,162 $ 523.64 Vested (132,745) $ 246.88 Forfeited (62,976) $ 280.97 Outstanding, December 31, 2020 386,383 $ 360.90 1.85 $ 225.2
Employee Stock Purchase Plan, Valuation Assumptions	The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions: Year Ended December 31, 2020 2019 2018 Expected volatility 41 % 31 % 27 % Risk-free interest rate 0.5 % 2.25 % 1.82 % Expected life (in years) 0.25 0.25 0.25 Expected dividend — — — Weighted-average fair value of purchase rights $ 94.93 $ 60.39 $ 55.04

10. Other Income and Expenses (

10. Other Income and Expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Other Income and Expenses [Abstract]
Schedule of other income (expense), net	Other (income) expense, net includes the following components (in millions): Year Ended December 31, 2020 2019 2018 Interest and investment income $ (18.2) $ (30.5) $ (26.6) Net realized gains on investments (1.0) (1.5) (1.6) Other-than-temporary impairment losses on investments 4.6 5.8 0.8 Gain on sale of land — — (4.1) Gain on divestiture of a division (11.7) — (5.1) Other expense 1.8 0.1 — Other income, net $ (24.5) $ (26.1) $ (36.6)

11. Supplemental Cash Flow In_2

11. Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2020
Supplemental Cash Flow Information [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	11. SUPPLEMENTAL CASH FLOW INFORMATION The reconciliation of net income to net cash provided by operating activities is as follows (in millions): Year Ended December 31, 2020 2019 2018 Net income $ 3,806.3 $ 1,758.7 $ 365.6 Adjustments to reconcile net income to net cash provided by operating activities Depreciation and amortization 138.1 134.2 138.1 Reduction in the carrying amount of right-of-use assets 37.1 40.3 — Share-based compensation 41.6 35.6 27.8 Gains on dispositions of securities (0.7) (1.5) (1.6) Other-than-temporary impairment losses on investments 4.6 5.8 0.8 Changes in fair market value of equity securities (4,495.8) (2,031.0) (606.2) Losses on dispositions of fixed assets 1.1 1.2 2.0 Gain on sale of land — — (4.1) Gain on divestiture of a division (11.7) — (5.1) Payments for operating lease liabilities (36.5) (38.6) — Changes in fair value of contingent consideration (1.0) (1.6) (6.2) (Increase) decrease in accounts receivable, net (15.0) 1.6 59.7 (Increase) decrease in inventories, net (52.1) 24.2 (12.9) (Increase) decrease in other current assets (8.4) 61.8 (15.3) Increase (decrease) in accounts payable and other current liabilities 124.7 10.6 (45.6) Increase (decrease) in income taxes payable 39.0 (4.2) (20.9) Increase in deferred income taxes 978.9 450.2 120.9 (Increase) decrease in other long term assets (6.4) (1.7) 1.1 Increase (decrease) in other long term liabilities 26.9 13.4 (10.0) Impairment losses on goodwill and long-lived assets — — 292.5 Other 4.6 (1.1) 4.9 Net cash provided by operating activities $ 575.3 $ 457.9 $ 285.5 Non-cash investing activities: Purchased property, plant and equipment $ 1.2 $ 8.1 $ 5.7 Purchased marketable securities and investments $ 4.6 $ 1.4 $ 0.8 Sold marketable securities and investments $ — $ 1.3 $ —

12. Commitments & Contingent _2

12. Commitments & Contingent Liabilities Commitments & Contingent Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Obligations and Funded Status [Abstract]
Schedule of Net Benefit Costs [Table Text Block]	Components of Net Periodic Benefit Cost The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions): 2020 2019 2018 Service costs $7.8 $6.9 $7.5 Interest costs 0.8 1.5 1.1 Expected returns on plan assets (0.7) (1.2) (1.1) Amortization of actuarial losses 1.3 1.0 1.3 Amortization of prior service costs — — 0.1 Settlements 1.3 0.9 — Net periodic benefit costs $10.5 $9.1 $8.9
Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]	Obligations and Funded Status The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in the Consolidated Balance Sheets for the plans (in millions): Change in benefit obligation: 2020 2019 Benefit obligation at beginning of year $153.8 $137.3 Service cost 7.8 6.9 Interest cost 0.8 1.5 Plan participants' contributions 4.1 3.5 Actuarial loss 5.3 11.9 Gross benefits paid (1.7) (2.1) Plan amendments — 0.2 Settlements (6.4) (3.8) Change attributable to foreign exchange 13.8 (1.6) Benefit obligation at end of year 177.5 153.8 Change in plan assets: Fair value of plan assets at beginning year 72.3 66.9 Actual return on plan assets 0.6 0.9 Employer contributions 4.1 4.7 Plan participants' contributions 4.0 3.8 Gross benefits paid 0.2 (0.8) Settlements (6.4) (3.8) Change attributable to foreign exchange 6.6 0.6 Fair value of plan assets at end of year 81.4 72.3 Under funded status of plans $(96.1) $(81.5) Amounts recognized in the consolidated balance sheets: Current liabilities (Accrued payroll and employee benefits) $(1.3) $(1.1) Noncurrent liabilities (Other long-term liabilities) (94.8) (80.4) Net liability, end of fiscal year $(96.1) $(81.5)
Defined Benefit Plan, Assumptions [Table Text Block]	Assumptions The above actuarial net losses were primarily based on financial, demographic and experience assumptions. The weighted-average assumptions used in computing the benefit obligations are as follows: 2020 2019 Discount rate 0.3 % 0.5 % Compensation rate increase 1.7 % 1.7 % The weighted-average assumptions used in computing the net periodic benefit costs are as follows: 2020 2019 2018 Discount rate 0.5 % 1.1 % 0.8 % Expected long-term rate of return on plan assets 1.5 % 1.8 % 1.8 %

14. Segment Reporting (Tables)

14. Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Information regarding industry segments	Information regarding industry segments at December 31, 2020, 2019, and 2018 and for the years then ended is as follows (in millions): Life Clinical Other Segment net sales 2020 $ 1,231.8 $ 1,305.2 $ 8.6 2019 885.9 1,412.0 13.8 2018 861.7 1,411.8 15.9 Allocated interest expense 2020 $ 8.0 $ 13.8 $ 0.1 2019 7.4 15.9 0.1 2018 7.2 16.7 0.1 Depreciation and amortization 2020 $ 32.8 $ 65.1 $ 1.0 2019 29.4 71.7 0.9 2018 34.1 72.0 0.5 Segment profit (loss) 2020 $ 256.3 $ 149.1 $ (0.6) 2019 72.1 148.5 (1.5) 2018 28.7 (145.7) 0.2 Segment assets 2020 $ 607.3 $ 1,065.6 $ 9.5 2019 496.1 1,075.8 9.2 Capital expenditures 2020 $ 16.8 $ 43.6 $ 3.1 2019 16.6 58.9 0.6
Reconciliation of segment profit to consolidated income before taxes	The following reconciles total segment profit to consolidated income before taxes (in millions): Year Ended December 31, 2020 2019 2018 Total segment profit (loss) $ 404.8 $ 219.1 $ (116.8) Foreign currency exchange losses, net (1.8) (2.2) (2.9) Net corporate operating and other expense not allocated to segments (15.7) (12.9) (10.4) Change in fair market value of equity securities 4,495.8 2,031.0 606.2 Other income, net 24.5 26.1 36.6 Consolidated income before income taxes $ 4,907.6 $ 2,261.1 $ 512.7
Reconciliation of Assets from Segment to Consolidated	The following reconciles total segment assets to consolidated total assets (in millions): December 31, 2020 2019 Total segment assets $ 1,682.4 $ 1,581.1 Cash and other current assets 1,098.2 1,233.5 Property, plant and equipment, net, and operating lease right-of-use assets, excluding segment specific balances 52.7 56.0 Goodwill, net 291.9 264.1 Other long-term assets 9,847.4 4,863.4 Total assets $ 12,972.6 $ 8,008.9
Net sales and assets to external customers by geographic area	The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions): Year Ended December 31, 2020 2019 2018 Europe $ 857.7 $ 770.3 $ 792.0 Asia 546.5 505.0 495.5 United States 1,004.8 899.1 863.6 Other (primarily Canada and Latin America) 136.6 137.3 138.3 Total net sales $ 2,545.6 $ 2,311.7 $ 2,289.4 The following presents Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions): December 31, 2020 2019 Europe $ 208.6 $ 198.3 Asia 53.3 51.5 United States 454.4 468.7 Other (primarily Canada and Latin America) 12.0 12.7 Total Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes $ 728.3 $ 731.2

15. Restructuring Costs (Tables

15. Restructuring Costs (Tables)	12 Months Ended
	Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs [Table Text Block]	The following table summarizes the activity for the facility closure restructuring reserves for severance and exit costs (in millions): 2020 2019 Balance as of January 1 $ 3.2 $ 4.1 Adjustment to expense — (0.1) Cash payments (1.8) (0.7) Foreign currency translation losses (gains) 0.2 (0.1) Balance as of December 31 $ 1.6 $ 3.2 2020 2019 Life Science Clinical Diagnostics Total Life Science Clinical Diagnostics Total Balance as of January 1 $ 6.2 $ 19.1 $ 25.3 $ — $ — $ — Charged to expense — — — 6.2 19.1 25.3 Adjustment to expense (0.6) (4.2) (4.8) — — — Cash payments (4.7) (13.4) (18.1) (0.4) (0.7) (1.1) Reserve transferred from prior restructuring plan — — — 0.3 0.4 0.7 Foreign currency translation losses — 0.4 0.4 0.1 0.3 0.4 Balance as of December 31 $ 0.9 $ 1.9 $ 2.8 $ 6.2 $ 19.1 $ 25.3 The following table summarizes the restructuring activities related to the finance and administrative reorganization (in millions): 2020 Life Science Clinical Diagnostics Total Balances as of January 1 $ — $ — $ — Charged to expense 1.5 2.3 3.8 Adjustment to expense 0.1 — 0.1 Cash payments (0.5) (0.8) (1.3) Foreign currency translation losses — 0.1 0.1 Balances as of December 31 $ 1.1 $ 1.6 $ 2.7

16. Leases (Tables)

16. Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Lease, Cost [Table Text Block]	The components of lease expense were as follows (in millions): Twelve Months Ended December 31, 2020 2019 Operating lease cost $ 45.4 $ 51.4 Finance lease cost: Amortization of right-to-use assets $0.6 $ 0.6 Interest on lease liabilities $0.8 0.9 Total finance lease cost $ 1.4 $ 1.5 Sublease income $ 3.0 $ 3.0
Lessee Supplemental Cash Flow Information [Table Text Block]	Supplemental cash flow information related to leases was as follows (in millions): Twelve Months Ended December 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 44.4 $ 47.2 Operating cash flows from finance leases $ 0.6 $ 0.9 Financing cash flows from finance leases $ 0.8 $ 0.6 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 16.1 $ 28.7 Finance leases $ 0.4 $ 0.2
Lessee Supplemental Balance Sheet Information [Table Text Block]	Supplemental balance sheet information related to leases was as follows (in millions): December 31, 2020 2019 Operating Leases Operating lease right-of-use assets $ 202.1 $ 201.9 Current operating lease liabilities $ 36.5 $ 35.4 Operating lease liabilities 175.1 176.0 Total operating lease liabilities $ 211.6 $ 211.4 Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities. December 31, 2020 2019 Finance Leases Property, plant and equipment, gross $ 12.2 $ 11.4 Less: accumulated depreciation and amortization (5.0) (4.2) Property, plant and equipment, net $ 7.2 $ 7.2 Current maturities of long-term debt and notes payable $ 0.5 $ 0.5 Long-term debt, net of current maturities 11.0 11.2 Total finance lease liabilities $ 11.5 $ 11.7 December 31, 2020 2019 Weighted Average Remaining Lease Term Operating leases - in years 8 9 Finance leases - in years 16 18 Weighted Average Discount Rate Operating leases 3.9 % 4.2 % Finance leases 6.2 % 6.5 %
Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]	Maturities of lease liabilities were as follows (in millions): Year Ending December 31, Operating Leases Finance Leases 2021 $ 43.6 $ 1.3 2022 36.5 1.2 2023 31.9 1.2 2024 27.2 1.2 2025 23.2 1.1 Thereafter 90.5 14.0 Total lease payments 252.9 20.0 Less imputed interest (41.3) (8.5) Total $ 211.6 $ 11.5

17. Quarterly Financial Data (T

17. Quarterly Financial Data (Tables)	12 Months Ended
	Dec. 31, 2020
Quarterly Financial Data [Abstract]
Schedule of Quarterly Financial Data [Table Text Block]	First Second Third Fourth 2020 Net sales $ 571.6 $ 536.9 $ 647.3 $ 789.8 Gross profit $ 317.4 $ 293.0 $ 367.3 $ 460.1 Net income $ 685.9 $ 966.4 $ 1,314.8 $ 839.2 Basic earnings per share $ 22.97 $ 32.59 $ 44.24 $ 28.13 Diluted earnings per share $ 22.72 $ 32.15 $ 43.64 $ 27.81 2019 Net sales $ 554.0 $ 572.6 $ 560.6 $ 624.5 Gross profit $ 311.8 $ 307.8 $ 307.0 $ 330.4 Net income (loss) $ 865.2 $ 598.8 $ (258.8) $ 553.5 Basic earnings (loss) per share $ 29.03 $ 20.08 $ (8.68) $ 18.50 Diluted earnings (loss) per share $ 28.74 $ 19.86 $ (8.68) $ 18.31

1. Significant Accounting Pol_4

1. Significant Accounting Policies Property, Plant and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Restricted investments	$ 5,560	$ 5,560
Retained earnings	9,268,012	5,470,779
Other assets	86,723	79,636
Prepaid Taxes	5,800
Income Tax Expense (Benefit)	(1,101,371)	(502,406)	$ (147,045)
Intangible Assets, Net (Excluding Goodwill)	$ 199,497	$ 145,525
Minimum [Member]
Property, Plant and Equipment [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years
Minimum [Member] | Building and Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Minimum [Member] | Reagent Rental Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	1 year
Minimum [Member] | Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Finite-Lived Intangible Asset, Useful Life	20 years
Maximum [Member] | Building and Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	50 years
Maximum [Member] | Reagent Rental Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Maximum [Member] | Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	12 years

1. Significant Accounting Pol_5

1. Significant Accounting Policies Warranty rollforward (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Movement in Standard Product Warranty Accrual [Roll Forward]
Warranty accrual, beginning of period	$ 9	$ 10.1	$ 18.7
Provision for warranty	9.4	9.9	25.5
Actual warranty costs	(8.6)	(11)	(34.1)
Warranty accrual, end of period	$ 9.8	$ 9	$ 10.1

1. Significant Accounting Pol_6

1. Significant Accounting Policies Earnings per share (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Basic weighted average shares outstanding	29,768	29,843	29,836
Effect of potentially dilutive stock options and restricted stock awards	392	341	392
Diluted weighted average common shares	30,160	30,184	30,228
Anti-dilutive shares excluded from the computation of diluted EPS	44	98	84

1. Significant Accounting Pol_7

1. Significant Accounting Policies Details (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest expense		$ 21,861	$ 23,416	$ 23,962
Selling, general and administrative expense		800,267	824,625	834,783
Research and development expense		226,598	202,710	199,196
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)					$ 70,000
Stockholders' Equity Attributable to Parent	$ 9,879,940	9,879,940	5,755,057	4,020,331	$ 2,930,250
Restricted investments	5,560	5,560	5,560
Retained earnings	9,268,012	9,268,012	5,470,779
Prepaid Taxes	(5,800)	(5,800)
Accumulated other comprehensive (loss) income	282,456	282,456	(87,348)
Other (income) expense, net		24,488	26,094	36,593
Deferred Tax Assets, Gross	247,000	247,000	205,200
Unrealized Gain on Securities		4,495,825	2,030,987	606,230
Deferred Income Tax Expense (Benefit)		979,000	450,200	120,900
Cost of Goods and Services Sold		1,107,804	1,054,663	1,066,264
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Increase				(49,000)
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)		0	0	10,500
Goodwill, Impairment Loss		0	0	282,000
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)		1,200	(1,200)	3,900
Accounts Receivable, Allowance for Credit Loss, Writeoff		(1,600)	(6,600)	(2,700)
Accounts Receivable, Allowance for Credit Loss, Recovery		0	1,300	0
Litigation Settlement, Amount Awarded from Other Party	35,300
Trading Revenue [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Litigation Settlement, Amount Awarded from Other Party	$ 32,300
Clinical Diagnostics [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest expense		13,800	15,900	16,700
Goodwill, Impairment Loss				276,100
Life Science [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest expense		$ 8,000	$ 7,400	7,200
Goodwill, Impairment Loss				$ 5,900

1. Significant Accounting Pol_8

1. Significant Accounting Policies Revenue Recognition (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disaggregation of Revenue [Line Items]
Cost of Goods and Services Sold	$ 1,107,804	$ 1,054,663	$ 1,066,264
Retained earnings	$ 9,268,012	$ 5,470,779
Revenue Allocation Percent To Lease Elements	3.00%	3.00%	5.00%
Deferred Revenue	$ 60,000	$ 45,800
Deferred revenue	$ 42,468	$ 33,735

1. Significant Accounting Pol_9

1. Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Accounts Receivable, Allowance for Credit Loss	$ 19,807	$ 19,807	$ 20,205	$ 26,700	$ 25,500
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)		1,200	(1,200)	3,900
Accounts Receivable, Allowance for Credit Loss, Writeoff		(1,600)	(6,600)	(2,700)
Accounts Receivable, Allowance for Credit Loss, Recovery		0	1,300	0
Litigation Settlement, Amount Awarded from Other Party	$ 35,300
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)		0	0	10,500
Goodwill, Impairment Loss		$ 0	$ 0	$ 282,000

2. Acquisitions (Details)

2. Acquisitions (Details) - USD ($) $ in Thousands	3 Months Ended					12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Apr. 01, 2020	Oct. 01, 2019	Aug. 02, 2019	Mar. 04, 2019
Business Acquisition [Line Items]
Business Combination, Consideration Transferred	$ 99,300	$ 4,200	$ 60,000	$ 20,000
Payments to Acquire Businesses, Net of Cash Acquired		3,600	59,700	16,000	$ 4,000
Business Combination, Contingent Consideration, Liability									$ 100	$ 600
Business Combination, Separately Recognized Transactions, Revenues and Gains Recognized		400
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles										3,400	$ 26,800	$ 5,500
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets									8,400	200
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities									19,700
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets												$ 200
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net									300	$ 1,400	$ 4,200
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets									69,500
Goodwill		264,131			$ 219,800	$ 291,916	$ 264,131	$ 219,800
Goodwill, Acquired During Period	29,800		$ 28,700	15,600		29,800	44,300
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net									99,300
Business Combination, Consideration Transferred, Liabilities Incurred		$ 800		$ 1,300
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High									60,000
Payments to Acquire Businesses, Gross	99,200
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents									600
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill									79,900
Amortization expense						27,500	23,500	28,300
Goodwill, Other Increase (Decrease)						2,000	0
Proceeds from Divestiture of a Division	12,200					12,240	0	6,964
Gain on divestiture of a division	11,700					(11,700)	$ 0	$ (5,100)
Developed Technology Rights [Member]
Business Acquisition [Line Items]
Finite-lived Intangible Assets Acquired	$ 70,300
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	18 years 10 months 24 days
Customer Lists
Business Acquisition [Line Items]
Finite-lived Intangible Assets Acquired	$ 3,600
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	4 years
Noncompete Agreements [Member]
Business Acquisition [Line Items]
Finite-lived Intangible Assets Acquired	$ 1,400
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	3 years
In Process Research and Development [Member]
Business Acquisition [Line Items]
Finite-lived Intangible Assets Acquired	$ 4,600
Analytical Flow Cytometer Platform [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability						0
Celsee [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability						100			$ 100
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High						60,000
Celsee [Member] | Cost of Sales [Member]
Business Acquisition [Line Items]
Amortization expense						2,800
Celsee [Member] | Customer Lists | Selling, General and Administrative Expenses [Member]
Business Acquisition [Line Items]
Amortization expense						700
Celsee [Member] | Noncompete Agreements [Member] | Selling, General and Administrative Expenses [Member]
Business Acquisition [Line Items]
Amortization expense						$ 400

3. Fair Value Measurements (Det

3. Fair Value Measurements (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2020	Apr. 01, 2020	Dec. 31, 2019		Oct. 01, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities, FV-NI, Unrealized Gain		$ 4,495.8
Debt Securities, Available-for-sale		267.6
Business Combination, Contingent Consideration, Liability			$ 0.1			$ 0.6
Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		0
Distributor [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		0.6
Celsee [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		0.1	$ 0.1
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		6.7		$ 5.6
Equity Securities, FV-NI		9,582.4		4,664.4
Debt Securities, Available-for-sale		267.6		402.9
Forward foreign exchange contracts, Asset	[1]	1		0.9
Financial Assets Carried at Fair Value		9,990.5		5,227.9
Forward foreign exchange contracts, Liability	[2]	1		1
Business Combination, Contingent Consideration, Liability	[3]	0.7		4.9
Liabilities, Fair Value Disclosure		1.7		5.9
Fair Value, Recurring [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		36.2		72.9
Fair Value, Recurring [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		133.2		204.5
Fair Value, Recurring [Member] | US Government Sponsored Agencies [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		76.9		106.1
Fair Value, Recurring [Member] | Foreign Government Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		4		4.7
Fair Value, Recurring [Member] | Foreign Government Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		2.1		3.1
Fair Value, Recurring [Member] | Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		15.2		11.6
Fair Value, Recurring [Member] | Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		267.6		402.9
Fair Value, Recurring [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	41.7		42.9
Fair Value, Recurring [Member] | Time Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	27.6		41.2
Fair Value, Recurring [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		0.9		0.1	[4]
Fair Value, Recurring [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	60.1		69.9
Fair Value, Recurring [Member] | US Government Sponsored Agencies [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		2.5
Fair Value, Recurring [Member] | Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	132.8		154.1
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		6.7		5.6
Equity Securities, FV-NI		9,582.4		4,664.4
Debt Securities, Available-for-sale		0		0
Forward foreign exchange contracts, Asset	[1]	0		0
Financial Assets Carried at Fair Value		9,666.8		4,771.1
Forward foreign exchange contracts, Liability	[2]	0		0
Business Combination, Contingent Consideration, Liability	[3]	0		0
Liabilities, Fair Value Disclosure		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Government Sponsored Agencies [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Foreign Government Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Foreign Government Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Time Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	17.6		31.2
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	60.1		69.9
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Government Sponsored Agencies [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	77.7		101.1
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		0		0
Equity Securities, FV-NI		0		0
Debt Securities, Available-for-sale		267.6		402.9
Forward foreign exchange contracts, Asset	[1]	1		0.9
Financial Assets Carried at Fair Value		323.7		456.8
Forward foreign exchange contracts, Liability	[2]	1		1
Business Combination, Contingent Consideration, Liability	[3]	0		0
Liabilities, Fair Value Disclosure		1		1
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		36.2		72.9
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		133.2		204.5
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Government Sponsored Agencies [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		76.9		106.1
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Foreign Government Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		4		4.7
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Foreign Government Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		2.1		3.1
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		15.2		11.6
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	41.7		42.9
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Time Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	10		10
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		0.9		0.1
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Government Sponsored Agencies [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		2.5
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	55.1		53
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		0		0
Equity Securities, FV-NI		0		0
Debt Securities, Available-for-sale		0		0
Forward foreign exchange contracts, Asset	[1]	0		0
Financial Assets Carried at Fair Value		0		0
Forward foreign exchange contracts, Liability	[2]	0		0
Business Combination, Contingent Consideration, Liability	[3]	0.7		4.9
Liabilities, Fair Value Disclosure		0.7		4.9
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Government Sponsored Agencies [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Foreign Government Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Foreign Government Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Time Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Government Sponsored Agencies [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	0		0
Other Current Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		0.6		3.3
Short-term Investments [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities, FV-NI		61.4		51
Debt Securities, Available-for-sale		267.5		402.8
Short-term Investments [Member] | Fair Value, Recurring [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		36.1		72.8
Short-term Investments [Member] | Fair Value, Recurring [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		133.2		204.5
Short-term Investments [Member] | Fair Value, Recurring [Member] | US Government Sponsored Agencies [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		76.9		106.1
Short-term Investments [Member] | Fair Value, Recurring [Member] | Foreign Government Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		4		4.7
Short-term Investments [Member] | Fair Value, Recurring [Member] | Foreign Government Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		2.1		3.1
Short-term Investments [Member] | Fair Value, Recurring [Member] | Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		15.2		11.6
Short-term Investments [Member] | Fair Value, Recurring [Member] | Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		267.5		402.8
Other Investments [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		1.1		0
Equity Securities, FV-NI		9,521		4,613.4
Debt Securities, Available-for-sale		0.1		0.1
Other Noncurrent Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		0.1		1.6
Restricted investment | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		5.6		5.6
Other Long-term Investments [Member] | Fair Value, Recurring [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0.1		0.1
Other Long-term Investments [Member] | Fair Value, Recurring [Member] | Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		$ 0.1		$ 0.1
[1]	Forward foreign exchange contracts in an asset position are included in other current assets in the consolidated balance sheets.
[2]	Forward foreign exchange contracts in a liability position are included in other current liabilities in the consolidated balance sheets.
[3]	Contingent consideration liabilities are included in the following accounts in the consolidated balance sheets (in millions): December 31, 2020 December 31, 2019 Other current liabilities $ 0.6 $ 3.3 Other long-term liabilities 0.1 1.6 Total $ 0.7 $ 4.9
[4]	Cash equivalents are included in Cash and cash equivalents in the consolidated balance sheets.

3. Fair Value Measurements Fore

3. Fair Value Measurements Foreign Exchange Forward Contracts (Details) $ in Millions	12 Months Ended
	Dec. 31, 2020USD ($)
Forward foreign exchange contract to purchase foreign currency [Member]
Derivatives, Fair Value [Line Items]
Gain (loss) on foreign currency derivative instruments not designated as hedging instruments	$ 0.4
Derivative, Notional Amount	301.6
Forward foreign exchange contract to sell foreign currency [Member]
Derivatives, Fair Value [Line Items]
Gain (loss) on foreign currency derivative instruments not designated as hedging instruments	(0.4)
Derivative, Notional Amount	$ 125.3

3. Fair Value Measurements Avai

3. Fair Value Measurements Available-for-Sale Investments (Details) - USD ($) $ in Millions	Dec. 31, 2020	Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	$ 267.6
Debt Securities, Available-for-sale, Amortized Cost	262.2
Fair Value, Recurring [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	267.6	$ 402.9
Fair Value, Recurring [Member] | Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	133.2	204.5
Fair Value, Recurring [Member] | Municipal Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	15.2	11.6
Fair Value, Recurring [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	36.2	72.9
Fair Value, Recurring [Member] | US Government Sponsored Agencies [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	76.9	106.1
Fair Value, Recurring [Member] | Foreign Government Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	4	4.7
Fair Value, Recurring [Member] | Foreign Government Debt [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	2.1	3.1
Fair Value, Recurring [Member] | Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	267.6	402.9
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0	(0.4)
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	5.4	2.4
Debt Securities, Available-for-sale, Allowance for Credit Loss	0
Debt Securities, Available-for-sale, Amortized Cost	262.2	400.9
Short-term Investments [Member] | Fair Value, Recurring [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	267.5	402.8
Short-term Investments [Member] | Fair Value, Recurring [Member] | Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	133.2	204.5
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0	(0.1)
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	2.7	1.4
Debt Securities, Available-for-sale, Allowance for Credit Loss	0
Debt Securities, Available-for-sale, Amortized Cost	130.5	203.2
Short-term Investments [Member] | Fair Value, Recurring [Member] | Municipal Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	15.2	11.6
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0	0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	0.2	0.1
Debt Securities, Available-for-sale, Allowance for Credit Loss	0
Debt Securities, Available-for-sale, Amortized Cost	15	11.5
Short-term Investments [Member] | Fair Value, Recurring [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	36.1	72.8
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0	(0.1)
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	0.3	0.2
Debt Securities, Available-for-sale, Allowance for Credit Loss	0
Debt Securities, Available-for-sale, Amortized Cost	35.8	72.7
Short-term Investments [Member] | Fair Value, Recurring [Member] | US Government Sponsored Agencies [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	76.9	106.1
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0	(0.2)
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	2.2	0.7
Debt Securities, Available-for-sale, Allowance for Credit Loss	0
Debt Securities, Available-for-sale, Amortized Cost	74.7	105.6
Short-term Investments [Member] | Fair Value, Recurring [Member] | Foreign Government Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	4	4.7
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0	0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	0	0
Debt Securities, Available-for-sale, Allowance for Credit Loss	0
Debt Securities, Available-for-sale, Amortized Cost	4	4.7
Short-term Investments [Member] | Fair Value, Recurring [Member] | Foreign Government Debt [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	2.1	3.1
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0	0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	0	0
Debt Securities, Available-for-sale, Allowance for Credit Loss	0
Debt Securities, Available-for-sale, Amortized Cost	2.1	3.1
Short-term Investments [Member] | Fair Value, Recurring [Member] | Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	267.5	402.8
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0	(0.4)
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	5.4	2.4
Debt Securities, Available-for-sale, Allowance for Credit Loss	0
Debt Securities, Available-for-sale, Amortized Cost	262.1	400.8
Other Long-term Investments [Member] | Fair Value, Recurring [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	0.1	0.1
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0	0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	0	0
Debt Securities, Available-for-sale, Allowance for Credit Loss	0
Debt Securities, Available-for-sale, Amortized Cost	0.1	0.1
Other Long-term Investments [Member] | Fair Value, Recurring [Member] | Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	0.1	0.1
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0	0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	0	0
Debt Securities, Available-for-sale, Allowance for Credit Loss	0
Debt Securities, Available-for-sale, Amortized Cost	$ 0.1	$ 0.1

3. Fair Value Measurements Amor

3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details) $ in Millions	Dec. 31, 2020USD ($)
Fair Value Disclosures [Abstract]
Mature in less than one year	$ 130.9
Mature in one to five years	88.1
Mature in more than five years	43.2
Total Amortized Cost	262.2
Mature in less than one year	131.5
Mature in one to five years	90.5
Mature in more than five years	45.6
Estimated Fair Value	$ 267.6

3. Fair Value Measurements Fair

3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) $ in Millions	Dec. 31, 2019USD ($)
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months	$ 91.9
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	0.3
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer	19.9
Gross unrealized losses for investments in a loss position 12 months or more	0.1
Debt Securities, Available-for-sale, Unrealized Loss Position	111.8
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss	0.4
Asset-backed Securities [Member]
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months	17.9
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	0
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer	7
Gross unrealized losses for investments in a loss position 12 months or more	0.1
Debt Securities, Available-for-sale, Unrealized Loss Position	24.9
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss	0.1
Corporate Debt Securities [Member]
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months	46.5
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	0.1
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer	2.1
Gross unrealized losses for investments in a loss position 12 months or more	0
Debt Securities, Available-for-sale, Unrealized Loss Position	48.6
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss	0.1
US Government Sponsored Agencies [Member]
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months	27.5
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	0.2
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer	10.8
Gross unrealized losses for investments in a loss position 12 months or more	0
Debt Securities, Available-for-sale, Unrealized Loss Position	38.3
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss	$ 0.2

3. Fair Value Investments (Deta

3. Fair Value Investments (Details) - USD ($) $ in Millions	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2010
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity Securities without Readily Determinable Fair Value, Amount	$ 0.5	$ 0.3
Interest Receivable, Current	1.4	2
Equity Method Investments	$ 38.4	24.3
Senior Notes 4.875% due 2020 [Member] | Unsecured Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			4.875%
Ordinary voting shares [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment ownership percentage	37.00%
Investment Owned, Balance, Shares	12,987,900
Preference shares [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment ownership percentage	28.00%
Investment Owned, Balance, Shares	9,588,908
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt, Current	$ 0	424.4
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term Debt, Fair Value	$ 0	$ 435.5

3. Fair Value Measurements Cont

3. Fair Value Measurements Contingent Consideration (Details) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
		Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Apr. 01, 2020	Oct. 01, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value		$ 0.7	$ 0.7	$ 4.9
Business Combination, Contingent Consideration, Liability						$ 0.1	$ 0.6
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High						60
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability			(1)	(1.6)	$ (6.2)
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[1]	0.7	0.7	$ 4.9
Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		0	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements			(3.3)
Net (decrease) increase in estimated fair value of contingent consideration included in selling, general and administrative expense			(1)
Distributor [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		0.6	0.6
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements		(0.7)	(1.4)
Net (decrease) increase in estimated fair value of contingent consideration included in selling, general and administrative expense			0
Celsee [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		0.1	0.1			$ 0.1
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		$ 60	$ 60
Sales milestone percentage of annual invoices [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Contingent Consideration, Potential Percentage Payout		39.00%	39.00%
Sales milestone percentage of annual invoices low [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Contingent Consideration, Potential Percentage Payout		20.00%	20.00%
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low		$ 0	$ 0
[1]	Contingent consideration liabilities are included in the following accounts in the consolidated balance sheets (in millions): December 31, 2020 December 31, 2019 Other current liabilities $ 0.6 $ 3.3 Other long-term liabilities 0.1 1.6 Total $ 0.7 $ 4.9

4. Goodwill and other Purchased

4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details) - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
	Jun. 30, 2020	Sep. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Apr. 01, 2020
Goodwill [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill							$ 79,900
Goodwill [Roll Forward]
Goodwill period start			$ 555,000	$ 599,300	$ 555,000
Accumulated impairment loss period start			(335,200)	(335,200)	(335,200)
Goodwill, net period start			219,800	264,131	219,800
Goodwill, Acquired During Period	$ 29,800	$ 28,700	15,600	29,800	44,300
Goodwill, Other Increase (Decrease)				(2,000)	0
Goodwill, Impairment Loss				0	0	$ 282,000
Goodwill, Period Increase (Decrease)				27,800	44,300
Goodwill period end				627,100	599,300	555,000
Accumulated impairment loss period end				(335,200)	(335,200)	(335,200)
Goodwill, net period end				291,916	264,131	219,800
Life Science [Member]
Goodwill [Roll Forward]
Goodwill period start			234,500	250,100	234,500
Accumulated impairment loss period start			(41,800)	(41,800)	(41,800)
Goodwill, net period start			192,700	208,300	192,700
Goodwill, Acquired During Period				29,800	15,600
Goodwill, Other Increase (Decrease)				(2,000)	0
Goodwill, Impairment Loss						5,900
Goodwill, Period Increase (Decrease)				27,800	15,600
Goodwill period end				277,900	250,100	234,500
Accumulated impairment loss period end				(41,800)	(41,800)	(41,800)
Goodwill, net period end				236,100	208,300	192,700
Clinical Diagnostics [Member]
Goodwill [Roll Forward]
Goodwill period start			320,500	349,200	320,500
Accumulated impairment loss period start			(293,400)	(293,400)	(293,400)
Goodwill, net period start			$ 27,100	55,800	27,100
Goodwill, Acquired During Period				0	28,700
Goodwill, Other Increase (Decrease)				0	0
Goodwill, Impairment Loss						276,100
Goodwill, Period Increase (Decrease)				0	28,700
Goodwill period end				349,200	349,200	320,500
Accumulated impairment loss period end				(293,400)	(293,400)	(293,400)
Goodwill, net period end				$ 55,800	$ 55,800	$ 27,100

4. Goodwill and other Purchas_2

4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Oct. 01, 2019	Aug. 02, 2019	Mar. 04, 2019
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles				$ 3,400	$ 26,800	$ 5,500
Finite-Lived Intangible Assets, Gross	$ 608,100	$ 525,600
Future Amortization Expense, Year One	28,300
Future Amortization Expense, Year Two	25,100
Future Amortization Expense, Year Three	23,800
Future Amortization Expense, Year Four	20,700
Future Amortization Expense, Year Five	18,700
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	78,100
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated Amortization	(413,400)	(380,300)
Net Carrying Amount	194,700	145,300
Amortization [Abstract]
Amortization expense	27,500	23,500	$ 28,300
Impairment losses on goodwill and long-lived assets	0	0	292,513
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	0	0	$ 10,500
Intangible Assets, Net (Excluding Goodwill)	199,497	145,525
Intangible Assets, Gross (Excluding Goodwill)	$ 612,900	$ 525,800
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	5 years 6 months 3 days	6 years 4 months 9 days
Finite-Lived Intangible Assets, Gross	$ 116,600	$ 107,200
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated Amortization	(87,200)	(74,300)
Net Carrying Amount	$ 29,400	$ 32,900
Know how [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	4 years 9 months	5 years 8 months 15 days
Finite-Lived Intangible Assets, Gross	$ 196,600	$ 188,500
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated Amortization	(175,400)	(162,600)
Net Carrying Amount	$ 21,200	$ 25,900
Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	14 years	8 years 3 months 21 days
Finite-Lived Intangible Assets, Gross	$ 218,100	$ 144,200
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated Amortization	(107,100)	(93,900)
Net Carrying Amount	$ 111,000	$ 50,300
Licensing Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	7 years 8 months 23 days	8 years 8 months 26 days
Finite-Lived Intangible Assets, Gross	$ 65,600	$ 76,000
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated Amortization	(37,400)	(44,400)
Net Carrying Amount	$ 28,200	$ 31,600
Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	7 years 9 months 25 days	8 years 6 months
Finite-Lived Intangible Assets, Gross	$ 6,600	$ 6,400
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated Amortization	(4,200)	(3,600)
Net Carrying Amount	$ 2,400	$ 2,800
Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	3 years 10 months 13 days	6 years 3 days
Finite-Lived Intangible Assets, Gross	$ 4,500	$ 3,200
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated Amortization	(2,000)	(1,400)
Net Carrying Amount	$ 2,500	$ 1,800
Other Intangible Assets [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period
Finite-Lived Intangible Assets, Gross	$ 100	$ 100
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated Amortization	(100)	(100)
Net Carrying Amount	0	0
In Process Research and Development [Member]
Amortization [Abstract]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 4,800	$ 200

5. Notes Payable and Long-Ter_3

5. Notes Payable and Long-Term Debt (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Apr. 30, 2019	Dec. 31, 2010
Debt Instrument [Line Items]
Debt and Lease Obligation	$ 14,100,000	$ 439,800,000
Other Long-term Debt, Current	1,800,000	426,200,000
Long-term Debt and Lease Obligation	12,258,000	13,579,000
Maturities of Long-term Debt [Abstract]
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months	1,800,000
Long-term Debt, Maturities, Repayments of Principal in Year Two	1,800,000
Long-term Debt, Maturities, Repayments of Principal in Year Three	400,000
Long-term Debt, Maturities, Repayments of Principal in Year Four	400,000
Long-term Debt, Maturities, Repayments of Principal in Year Five	400,000
Long-term Debt, Maturities, Repayments of Principal after Year Five	9,300,000
Line of Credit Facility, Remaining Borrowing Capacity	207,200,000
Letters of Credit Outstanding, Amount	4,900,000
Performance Guarantee [Member]
Maturities of Long-term Debt [Abstract]
Letters of Credit Outstanding, Amount	4,900,000
Unsecured Debt [Member] | Senior Notes 4.875% due 2020 [Member]
Debt Instrument [Line Items]
Unsecured Debt	0	425,000,000
Long-term debt	0	424,400,000		$ 422,600,000
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ 0	600,000
Debt Instrument, Interest Rate, Effective Percentage				4.946%
Face amount of debt sold				$ 425,000,000
Debt Instrument, Interest Rate, Stated Percentage				4.875%
Maturities of Long-term Debt [Abstract]
Debt Instrument, Redemption Price, Percentage	100.00%
Finance Lease Obligations [Member] | Finance Leases and Other Debt [Member]
Debt Instrument [Line Items]
Other Long-term Debt	$ 14,100,000	$ 15,400,000
Line of Credit [Member]
Maturities of Long-term Debt [Abstract]
Line of Credit Facility, Maximum Borrowing Capacity			$ 200,000,000
Long-term Line of Credit	$ 0
Line of Credit Facility, Interest Rate at Period End	1.375%
Letters of Credit Outstanding, Amount	$ 200,000

6. Income Taxes (Details)

6. Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Taxes [Line Items]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 0	$ 0	$ 4,400
Prepaid Taxes	5,800
U.S.	2,339,700	1,034,000	363,400
International	2,567,900	1,227,100	149,300
Income before income taxes	4,907,638	2,261,081	512,659
U.S. Federal	69,900	13,000	8,800
State	12,000	4,400	2,200
International	22,300	23,500	30,500
Current Income Tax Expense (Benefit)	104,200	40,900	41,500
U.S. Federal	893,500	409,700	114,000
State	54,000	24,400	6,600
International	31,500	16,100	300
Deferred tax benefit	979,000	450,200	120,900
Non-current tax expense (benefit)	18,200	11,300	(15,400)
Provision for income taxes	$ 1,101,371	$ 502,406	$ 147,045
U.S. statutory tax rate	21.00%	21.00%	21.00%
Impact of foreign operations	(9.90%)	(9.70%)	(4.10%)
Goodwill impairment	0.00%	0.00%	5.60%
State taxes	1.10%	1.00%	1.70%
Other	0.00%	(0.40%)	(1.40%)
Provision for income taxes	22.40%	22.20%	28.70%
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)				$ 70,000
Bad debt, inventory and warranty accruals	$ 29,600	$ 23,900
Other post-employment benefits, vacation and other reserves	29,800	23,000
Tax credit and net operating loss carryforwards	93,500	83,700
Other	44,800	26,000
Total gross deferred tax assets	247,000	205,200
Valuation allowance	(44,600)	(67,200)	$ (70,800)	(66,400)
Deductions	(22,600)	(3,600)	0
Total deferred tax assets	202,400	138,000
Property and equipment	37,000	38,400
Investments and intangible assets	2,143,400	1,001,400
Total deferred tax liabilities	2,227,200	1,086,200
Net deferred tax liabilities	(2,024,800)	(948,200)
Unrecognized tax benefits period start	39,200	29,800	54,900
Additions to tax positions related to prior years	14,000	7,600	600
Reductions to tax positions related to prior years	(1,500)	(700)	(20,200)
Additions to tax positions related to the current year	3,400	3,000	4,600
Settlements	0	0	(6,800)
Lapse of statute of limitations	(600)	(400)	(1,100)
Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation	1,300
Currency translation		(100)	(2,200)
Unrecognized tax benefits period end	55,800	39,200	29,800	$ 54,900
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	14,300	11,200	9,500
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	(2,800)	$ (1,700)	(1,400)
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	17,200
Tax Credit Carryforward, Amount	2,300
Operating Loss Carryforwards	$ 26,300
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Increase			$ (49,000)
Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent	22.00%	22.00%
Operating lease obligations [Member]
Income Taxes [Line Items]
Other	$ 49,300	$ 48,600
Foreign Tax Authority [Member]
Income Taxes [Line Items]
Deductions	(22,600)
Operating Loss Carryforward With No Expiration Date	$ 117,800
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Other reconciling items	10.20%	10.30%	15.50%
Tax Cuts and Jobs Act [Member]
Income Taxes [Line Items]
U.S. tax reform	0.00%	0.00%	(9.60%)
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Tax Credit Carryforward, Amount	$ 37,200
Operating Loss Carryforwards	64,500
8888 Foreign Governments [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	255,000
Including accrued interest and penalties [Member]
Income Taxes [Line Items]
Other	1,500
Unrecognized tax benefits period end	70,100
Net of prepaid taxes [Member]
Income Taxes [Line Items]
Unrecognized tax benefits period end	62,800
Operating lease assets [Member]
Income Taxes [Line Items]
Deferred Tax Liabilities, Leasing Arrangements	$ 46,800	$ 46,400

7. Stockholders' Equity (Detail

7. Stockholders' Equity (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Common Class A [Member]
Class of Stock [Line Items]
Shares, Issued	25,073	24,966	24,884	24,679
Stock Issued During Period, Shares, Conversion of Convertible Securities	(32)	(24)	(30)
Stock Issued During Period, Shares, New Issues	75	58	175
Common Stock, Voting Rights	0.1
Election Percentage for Board of Directors	25.00%
Common Class B [Member]
Class of Stock [Line Items]
Shares, Issued	5,076	5,090	5,096	5,108
Stock Issued During Period, Shares, Conversion of Convertible Securities	(32)	(24)	(30)
Stock Issued During Period, Shares, New Issues	18	18	18
Common Stock, Voting Rights	one

7. Stockholders' Equity Treasur

7. Stockholders' Equity Treasury Shares (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended						12 Months Ended
	Mar. 31, 2020	Nov. 30, 2019	Aug. 31, 2019	Jun. 30, 2019	May 31, 2019	Nov. 30, 2018	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2020	Dec. 31, 2017
Equity, Class of Treasury Stock [Line Items]
Treasury Stock, Shares	573,577	281,636	259,293		218,571	193,150			244,548
Stock Repurchase Program, Remaining Authorized Repurchase Amount	$ 73.1	$ 173.1	$ 181.1		$ 193.7	$ 201.1	$ 273.1		$ 186.1
Stock Repurchase Program, Authorized Amount							$ 200			$ 250
Treasury Stock, Shares, Acquired	291,941	22,343	14,745	25,977	25,421	178,911
Treasury Stock Acquired, Average Cost Per Share	$ 342.55	$ 358.04	$ 339.05	$ 292.01	$ 291.70	$ 273.39
Employee Stock [Member]
Equity, Class of Treasury Stock [Line Items]
Stock Issued During Period, Shares, Treasury Stock Reissued							(19,755)
Treasury Class-A [Member]
Equity, Class of Treasury Stock [Line Items]
Stock Issued During Period, Shares, Treasury Stock Reissued							(117,423)	(118,910)

8. Accumulated Other Comprehe_4

8. Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive (loss) income	$ 282,456	$ (87,348)
Other comprehensive income, net of tax	369,804	(40,390)	$ (106,495)
Foreign currency translation adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive (loss) income	298,600	(72,400)	(35,500)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	371,900	(36,500)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0	0
Other Comprehensive Income (Loss), Tax	(900)	(400)
Other comprehensive income, net of tax	371,000	(36,900)
Other Postretirement Benefit Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive (loss) income	(26,000)	(22,200)	(14,800)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	(5,300)	(10,000)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	300	1,500
Other Comprehensive Income (Loss), Tax	1,200	1,100
Other comprehensive income, net of tax	(3,800)	(7,400)
Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive (loss) income	9,800	7,200	3,300
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	4,000	4,800
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	(600)	(400)
Other Comprehensive Income (Loss), Tax	(800)	(500)
Other comprehensive income, net of tax	2,600	3,900
Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive (loss) income	282,400	(87,400)	$ (47,000)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	370,600	(41,700)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	(300)	1,100
Other Comprehensive Income (Loss), Tax	(500)	200
Other comprehensive income, net of tax	$ 369,800	$ (40,400)

8. Accumulated Other Comprehe_5

8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Selling, general and administrative expense	$ (800,267)	$ (824,625)	$ (834,783)
Realized Investment Gains (Losses)	$ 1,000	$ 1,500	$ 1,600

9. Share-based Compensation (De

9. Share-based Compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Exercise of Option, Tax Benefit	$ 11,200,000	$ 5,400,000	$ 5,400,000
Share-based Compensation Expense	41,600,000	35,600,000	27,800,000
Share-based Payment Arrangement, Expense, Tax Benefit	6,000,000	5,600,000	4,400,000
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Expense	6,400,000	4,800,000	3,500,000
cost of goods sold [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Expense	3,400,000	2,900,000	2,300,000
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Expense	$ 31,800,000	$ 27,900,000	22,000,000
2011 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Authorized	1,300,000
Stock Option and Award Plans [Member] | Incentive Award Plan 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Authorized	2,108,050
Number of Shares Available for Grant	1,451,617
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Remaining Contractual Term (in years) - Outstanding	4 years 7 months 20 days
Aggregate Intrinsic Value (in millions) - Outstanding	$ 110.2
Options - Weighted-Average Exercise Price	$ 196.29	$ 162.23
Options Granted - Weighted Average Exercise Price	524.30
Options Exercised - Weighted Average Exercise Price	112.96
Options Granted Term		10
Options Forfeitured/expired - Weighted Average Exercise Price	$ 269.64
Options - Shares Vested and Expected to Vest	73,126
Options Vested and Expected to Vest - Weighted Average Exercise Price	$ 364.07
Options Vested and Expected to Vest - Weighted Average Remaining Contractual Term (in years)	8 years 4 months 6 days
Options Vested and Expected to Vest - Aggregate Intrinsic Value (in millions)	$ 16
Weighted Average Exercise Price - Options Exercisable	$ 138.42
Weighted Average Remaining Contractual Term (in years) - Exercisable	3 years 4 months 9 days
Options Exercisable Aggregate Intrinsic Value (in millions)	$ 94.2
Options, Exercises in Period, Total Intrinsic Value	24,000,000	$ 12,000,000	8,000,000
Cash Received from Exercise of Stock Options	3,800,000	$ 2,600,000	$ 500,000
Total unrecognized compensation cost from stock options	$ 7,000,000
Options Number Exercisable	211,997
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%	20.00%
Weighted average fair value of options granted, period for recognition	3 years
Expected Volatility	27.00%	22.00%	22.00%
Risk Free Interest Rate	0.31%	1.69%	2.85%
Expected life (in years)	7 years 4 months 24 days	7 years 6 months	7 years 7 months 6 days
Expected dividend	$ 0	$ 0	$ 0
Weighted average fair value of options granted	$ 153.32	$ 93.96	$ 105.94
Expected dividend yield	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding beginning of period	344,522
Options - Shares Granted	22,527
Options - Shares Exercised	(66,085)
Options - Shares Forfeitures/expired	(15,841)
Outstanding end of period	285,123	344,522
Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Available for Grant	551,983
Cash Received from Exercise of Stock Options	$ 16,400,000	$ 14,300,000	$ 13,600,000
Stock Issued During Period, Shares, Employee Stock Purchase Plans	47,548	58,717	63,464
Employee Contribution Rate - Maximum	10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount	$ 25,000
Employee Purchase Price Discount from Market Price	85.00%
Expected Volatility	41.00%	31.00%	27.00%
Risk Free Interest Rate	0.50%	2.25%	1.82%
Expected life (in years)	3 months	3 months	3 months
Expected dividend	$ 0	$ 0	$ 0
Expected dividend yield	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased	$ 94.93	$ 60.39	$ 55.04

9. Share-based Compensation Res

9. Share-based Compensation Restricted Stock (Details) - Treasury Class-A [Member] - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 65	$ 44.8	$ 40
Total unrecognized compensation cost from restricted stock	$ 125.6
Nonvested shares - Weighted Average Grant Date Fair Value	$ 360.90	$ 279.14
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Outstanding beginning of period	469,942
Restricted Stock Units Granted	112,162
Restricted Stock Units - Vested	(132,745)
Restricted Stock Units - Forfeited	(62,976)
Outstanding end of period	386,383	469,942
Weighted Average Grant Date Fair Value - Granted	$ 523.64
Restricted Stock Units Vested - Weighted-Average Grant-Date Fair Value	246.88
Resticted Stock Units Cancelled/forfeited - Weighted-Average Grant-Date Fair Value	$ 280.97
Weighted Average Remaining Contractual Term (in years)	1 year 10 months 6 days
Resticted Stock Units Outstanding Aggregate Intrinsic Value (in millions)	$ 225.2
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	3 years

10. Other Income and Expenses_2

10. Other Income and Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Interest and investment income	$ (18,200)	$ (30,500)	$ (26,600)
Realized Investment Gains (Losses)	(1,000)	(1,500)	(1,600)
Other-than-temporary impairment losses on investments	4,600	5,800	800
Gain on sale of land	0	0	(4,100)
Gain on divestiture of division	(11,700)	0	(5,100)
Other Expense	1,800	100	0
Other income, net	$ (24,488)	$ (26,094)	$ (36,593)

11. Supplemental Cash Flow In_3

11. Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Other Significant Noncash Transactions [Line Items]
Net income	$ 839,200	$ 1,314,800	$ 966,400	$ 685,900	$ 553,500	$ (258,800)	$ 598,800	$ 865,200	$ 3,806,267	$ 1,758,675	$ 365,614
Depreciation and amortization									138,100	134,200	138,100
Reduction in the carrying amount of right-of-use assets									37,100	40,300	0
Share-based compensation									41,600	35,600	27,800
Gains on disposition of securities									(700)	(1,500)	(1,600)
Other than Temporary Impairment Losses on Investments									4,600	5,800	800
Changes in fair market value of equity securities									(4,495,800)	(2,031,000)	(606,200)
Losses on dispositions of fixed assets									1,100	1,200	2,000
Gain on sale of land									0	0	(4,100)
Gain on divestiture of a division			$ 11,700						(11,700)	0	(5,100)
Payments for operating lease liabilities									(36,500)	(38,600)	0
Changes in fair value of contingent consideration									(1,000)	(1,600)	(6,200)
(Increase) decrease in accounts receivable, net									(15,000)	1,600	59,700
(Increase) decrease in inventories, net									(52,100)	24,200	(12,900)
(Increase) decrease in Other Current Assets									(8,400)	61,800	(15,300)
Increase (decrease) in accounts payable and other current liabilities									124,700	10,600	(45,600)
Increase (decrease) in Income Taxes Payable									39,000	(4,200)	(20,900)
Increase in deferred income taxes									978,900	450,200	120,900
(Increase) decrease in other long term assets									(6,400)	(1,700)	1,100
Increase (Decrease) in Other Noncurrent Liabilities									26,900	13,400	(10,000)
Impairment losses on goodwill and long-lived assets									0	0	292,513
Other									4,600	(1,100)	4,900
Net cash provided by operating activities									575,328	457,897	285,494
Noncash purchased property, plant and equipment									1,200	8,100	5,700
Noncash Purchased Marketable Securities and Investments									4,600	1,400	800
Noncash or Part Noncash Acquisition, Accounts Receivable Acquired									$ 0	$ 1,300	$ 0

12. Commitments & Contingent _3

12. Commitments & Contingent Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2020	Dec. 31, 2019
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Post-Employment Benefits Liability	$ 4.1	$ 3.5
Recorded Unconditional Purchase Obligation	134
Recorded Unconditional Purchase Obligation Due in Next Twelve Months	2.7
Recorded Unconditional Purchase Obligation Due in Second Year	12
Recorded Unconditional Purchase Obligation Due in Third Year	7.3
Recorded Unconditional Purchase Obligation Due in Fourth Year	5.6
Recorded Unconditional Purchase Obligation Due in Fifth Year	3.8
Recorded Unconditional Purchase Obligation Due after Fifth Year	102.6
Unrecorded Unconditional Purchase Obligation	16.6
Unrecorded Unconditional Purchase Obligation, Due in Twelve Months	14.1
Unrecorded Unconditional Purchase Obligation, Due within Two Years	2.1
Unrecorded Unconditional Purchase Obligation, Due within Three Years	0.1
Unrecorded Unconditional Purchase Obligation, Due within Four Years	0.1
Unrecorded Unconditional Purchase Obligation, Due within Five Years	0.1
Unrecorded Unconditional Purchase Obligation, Due after Five Years	0.1
Letters of Credit Outstanding Amount	$ 4.9
Employees Covered By Collective Bargaining Agreements U.S., Percentage	7.00%
Defined Benefit Plan, Accumulated Benefit Obligation	$ 159.5	138.6
Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets	$ 78.1	$ 66.3
UNITED STATES
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Entity Number of Employees	3,180

12. Commitments & Contingent _4

12. Commitments & Contingent Liabilities Period Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Contribution expense	$ 10.6	$ 16.1	$ 15.9

12. Commitments & Contingent _5

12. Commitments & Contingent Liabilities Pensions (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	0.50%	1.10%	0.80%
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	0.30%	0.50%
Defined Benefit Plan, Benefit Obligation	$ 177.5	$ 153.8	$ 137.3
Defined Benefit Plan, Service Cost	7.8	6.9	7.5
Defined Benefit Plan, Interest Cost	0.8	1.5	1.1
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	4.1	3.5
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)	5.3	11.9
Defined Benefit Plan, Benefit Obligation, Benefits Paid	(1.7)	(2.1)
Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment	0	0.2
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement	(6.4)	(3.8)
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	13.8	(1.6)
Defined Benefit Plan, Plan Assets, Amount	81.4	72.3	66.9
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	0.6	0.9
Defined Benefit Plan, Plan Assets, Contributions by Employer	4.1	4.7
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	4	3.8
Defined Benefit Plan, Plan Assets, Benefits Paid	0.2	(0.8)
Defined Benefit Plan, Plan Assets, Payment for Settlement	(6.4)	(3.8)
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	6.6	0.6
Defined Benefit Plan, Funded (Unfunded) Status of Plan	(96.1)	(81.5)
Liability, Defined Benefit Plan, Current	(1.3)	(1.1)
Liability, Defined Benefit Plan, Noncurrent	(94.8)	(80.4)
Liability, Defined Benefit Plan	(96.1)	(81.5)
Defined Benefit Plan, Expected Return (Loss) on Plan Assets	(0.7)	(1.2)	(1.1)
Defined Benefit Plan, Amortization of Gain (Loss)	1.3	1	1.3
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0	0	0.1
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement	1.3	0.9	0
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	$ 10.5	$ 9.1	$ 8.9
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase	1.70%	1.70%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	1.50%	1.80%	1.80%
Defined Benefit Plan, Accumulated Benefit Obligation	$ 159.5	$ 138.6
Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets	$ 78.1	$ 66.3

14. Segment Reporting (Details)

14. Segment Reporting (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Segment Reporting Information [Line Items]
Number Of Products And Services	9,000
Net sales	$ 2,545,600	$ 2,311,700	$ 2,289,400
Interest expense	21,861	23,416	23,962
Depreciation and amortization	138,100	134,200	138,100
Segment profit	410,957	229,661	(103,341)
Total assets	12,972,618	8,008,859
Payments to Acquire Property, Plant, and Equipment	98,920	98,532	129,825
Life Science [Member]
Segment Reporting Information [Line Items]
Net sales	1,231,800	885,900	861,700
Interest expense	8,000	7,400	7,200
Depreciation and amortization	32,800	29,400	34,100
Segment profit	256,300	72,100	28,700
Total assets	607,300	496,100
Payments to Acquire Property, Plant, and Equipment	16,800	16,600
Clinical Diagnostics [Member]
Segment Reporting Information [Line Items]
Net sales	1,305,200	1,412,000	1,411,800
Interest expense	13,800	15,900	16,700
Depreciation and amortization	65,100	71,700	72,000
Segment profit	149,100	148,500	(145,700)
Total assets	1,065,600	1,075,800
Payments to Acquire Property, Plant, and Equipment	43,600	58,900
All Other Segments [Member]
Segment Reporting Information [Line Items]
Net sales	8,600	13,800	15,900
Interest expense	100	100	100
Depreciation and amortization	1,000	900	500
Segment profit	(600)	(1,500)	$ 200
Total assets	9,500	9,200
Payments to Acquire Property, Plant, and Equipment	$ 3,100	$ 600

14. Segment Information Segment

14. Segment Information Segment Profit Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Goodwill, Impairment Loss	$ 0	$ 0	$ 282,000
Income before income taxes	4,907,638	2,261,081	512,659
Unrealized Gain on Securities	4,495,825	2,030,987	606,230
Operating Segments [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	404,800	219,100	(116,800)
Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Unrealized Gain on Securities	4,495,800	2,031,000	606,200
Corporate, Non-Segment [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	(15,700)	(12,900)	(10,400)
Foreign Currency Gain (Loss) [Member] | Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	(1,800)	(2,200)	(2,900)
Other Nonoperating Income (Expense) [Member] | Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	$ 24,500	$ 26,100	36,600
Clinical Diagnostics [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Goodwill, Impairment Loss			$ 276,100

14. Segment Information Segme_2

14. Segment Information Segment Asset Reconciliation (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	$ 12,972,618	$ 8,008,859
Operating Segments [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	1,682,400	1,581,100
Other Current Assets [Member] | Segment Reconciling Items [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	1,098,200	1,233,500
Property, Plant and Equipment and Operating lease right-of-use assets excluding segment specific [Member] | Segment Reconciling Items [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	52,700	56,000
Goodwill [Member] | Segment Reconciling Items [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	291,900	264,100
Other Noncurrent Assets [Member] | Segment Reconciling Items [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	$ 9,847,400	$ 4,863,400

14. Segment Information Segme_3

14. Segment Information Segment Information by Geographical Location (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting Information [Line Items]
Net sales	$ 2,545.6	$ 2,311.7	$ 2,289.4
Other assets, property, plant and equipment, net and Operating lease right-of-use assets	728.3	731.2
Europe [Member]
Segment Reporting Information [Line Items]
Net sales	857.7	770.3	792
Other assets, property, plant and equipment, net and Operating lease right-of-use assets	208.6	198.3
Asia [Member]
Segment Reporting Information [Line Items]
Net sales	546.5	505	495.5
Other assets, property, plant and equipment, net and Operating lease right-of-use assets	53.3	51.5
UNITED STATES
Segment Reporting Information [Line Items]
Net sales	1,004.8	899.1	863.6
Other assets, property, plant and equipment, net and Operating lease right-of-use assets	454.4	468.7
Other (primarily Canada and Latin America) [Member]
Segment Reporting Information [Line Items]
Net sales	136.6	137.3	$ 138.3
Other assets, property, plant and equipment, net and Operating lease right-of-use assets	$ 12	$ 12.7

15. Restructuring Costs (Detail

15. Restructuring Costs (Details) - USD ($) $ in Millions	12 Months Ended			14 Months Ended	25 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2020
Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	$ 0	$ (0.1)
Restructuring Charges					$ 4
Restructuring Reserve	1.6	3.2	$ 4.1	$ 1.6	1.6
Payments for Restructuring	(1.8)	(0.7)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss	0.2	(0.1)
Facility Closing [Member] | Clinical Diagnostics [Member] | Other Operating Income (Expense) [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	0.1		0.2
Restructuring Charges		0
Facility Closing [Member] | Clinical Diagnostics [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	(0.1)	(0.1)
Restructuring Charges			3.9
Facility Closing [Member] | Accounts Payable and Accrued Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	1.5			1.5	1.5
Facility Closing [Member] | Other Current Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	0.1			0.1	0.1
European and North American Reorganization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	(4.8)	0
Restructuring Charges	0	25.3		20.5
Restructuring Reserve	2.8	25.3	0	2.8	2.8
Payments for Restructuring	(18.1)	(1.1)
Restructuring Reserve, Translation and Other Adjustment	0	0.7
Restructuring Reserve, Foreign Currency Translation (Gain) Loss	0.4	0.4
European and North American Reorganization [Member] | Cost of Goods and Service Benchmark [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	(1.9)
Restructuring Charges		4.8
European and North American Reorganization [Member] | Selling, General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	(1.7)
Restructuring Charges		14.4
European and North American Reorganization [Member] | Research and Development Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	(1.2)
Restructuring Charges		6.1
European and North American Reorganization [Member] | Life Science [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	(0.6)	0
Restructuring Charges	0	6.2
Restructuring Reserve	0.9	6.2	0	0.9	0.9
Payments for Restructuring	(4.7)	(0.4)
Restructuring Reserve, Translation and Other Adjustment	0	0.3
Restructuring Reserve, Foreign Currency Translation (Gain) Loss	0	0.1
European and North American Reorganization [Member] | Clinical Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	(4.2)	0
Restructuring Charges	0	19.1
Restructuring Reserve	1.9	19.1	$ 0	1.9	1.9
Payments for Restructuring	(13.4)	(0.7)
Restructuring Reserve, Translation and Other Adjustment	0	0.4
Restructuring Reserve, Foreign Currency Translation (Gain) Loss	0.4	0.3
Finance and Administrative Reorganization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	0.1
Restructuring Charges	3.8
Restructuring Reserve	2.7	0		2.7	2.7
Payments for Restructuring	(1.3)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss	0.1
Finance and Administrative Reorganization [Member] | Selling, General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	3.9
Finance and Administrative Reorganization [Member] | Life Science [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	0.1
Restructuring Charges	1.5
Restructuring Reserve	1.1	0		1.1	1.1
Payments for Restructuring	(0.5)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss	0
Finance and Administrative Reorganization [Member] | Clinical Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	0
Restructuring Charges	2.3
Restructuring Reserve	1.6	$ 0		$ 1.6	$ 1.6
Payments for Restructuring	(0.8)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss	$ 0.1

16. Leases (Details)

16. Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Lessee, Lease, Description [Line Items]
Deferred Tax Assets, Other	$ 44,800	$ 26,000
U.S.	2,339,700	$ 1,034,000	$ 363,400
Operating Leases, Rent Expense, Net			$ 47,400
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	43,600
Finance Lease, Liability, Payments, Remainder of Fiscal Year	$ 1,300
Operating Lease, Weighted Average Remaining Lease Term	8 years	9 years
Operating lease right-of-use asset	$ 202,136	$ 201,868
Operating Lease, Payments	44,400	47,200
Operating Lease, Cost	45,400	51,400
Finance Lease, Right-of-Use Asset, Amortization	600	600
Finance Lease, Interest Expense	800	900
Finance Lease Cost	1,400	1,500
Sublease Income	3,000	3,000
Finance Lease, Interest Payment on Liability	600	900
Finance Lease, Principal Payments	800	600
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	16,100	28,700
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	400	200
Current operating lease liabilities	36,507	35,365
Operating lease liabilities	175,128	176,018
Current maturities of long-term debt and notes payable	500	500
Finance Lease, Liability, Noncurrent	11,000	11,200
Operating Lease, Liability	$ 211,600	$ 211,400
Finance Lease, Weighted Average Remaining Lease Term	16 years	18 years
Operating Lease, Weighted Average Discount Rate, Percent	3.90%	4.20%
Finance Lease, Weighted Average Discount Rate, Percent	6.20%	6.50%
Lessee, Operating Lease, Liability, Payments, Due Year Two	$ 36,500
Finance Lease, Liability, Payments, Due Year Two	1,200
Lessee, Operating Lease, Liability, Payments, Due Year Three	31,900
Finance Lease, Liability, Payments, Due Year Three	1,200
Lessee, Operating Lease, Liability, Payments, Due Year Four	27,200
Finance Lease, Liability, Payments, Due Year Four	1,200
Lessee, Operating Lease, Liability, Payments, Due Year Five	23,200
Finance Lease, Liability, Payments, Due Year Five	1,100
Lessee, Operating Lease, Liability, Payments, Due after Year Five	90,500
Finance Lease, Liability, Payments, Due after Year Five	14,000
Lessee, Operating Lease, Liability, Payments, Due	252,900
Finance Lease, Liability, Payment, Due	20,000
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	(41,300)
Finance Lease, Liability, Undiscounted Excess Amount	(8,500)
Finance Lease, Liability	11,500	$ 11,700
Finance Lease, Right-of-Use Asset, before Accumulated Amortization	12,200	11,400
Finance Lease, Right-of-Use Asset, Accumulated Amortization	5,000	4,200
Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total	$ 7,200	$ 7,200
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lessee Operating And Finance Leases Remaining Lease Term	18 years
Minimum [Member]
Lessee, Lease, Description [Line Items]
Lessee Operating And Finance Leases Remaining Lease Term	1 year

17. Quarterly Financial Data (D

17. Quarterly Financial Data (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Quantifying Misstatement in Current Year Financial Statements [Line Items]
Unrealized Gain on Securities									$ 4,495,825	$ 2,030,987	$ 606,230
Net sales	$ 789,800	$ 647,300	$ 536,900	$ 571,600	$ 624,500	$ 560,600	$ 572,600	$ 554,000	2,545,626	2,311,659	2,289,415
Operating Income (Loss)									410,957	229,661	(103,341)
Cost of Goods and Services Sold									1,107,804	1,054,663	1,066,264
Gross profit	460,100	367,300	293,000	317,400	330,400	307,000	307,800	311,800	1,437,822	1,256,996	1,223,151
Selling, general and administrative expense									800,267	824,625	834,783
Research and development expense									226,598	202,710	199,196
Net Income (Loss) Attributable to Parent	$ 839,200	$ 1,314,800	$ 966,400	$ 685,900	$ 553,500	$ (258,800)	$ 598,800	$ 865,200	$ 3,806,267	$ 1,758,675	$ 365,614
Earnings Per Share, Basic	$ 28.13	$ 44.24	$ 32.59	$ 22.97	$ 18.50	$ (8.68)	$ 20.08	$ 29.03	$ 127.86	$ 58.93	$ 12.25
Earnings Per Share, Diluted	$ 27.81	$ 43.64	$ 32.15	$ 22.72	$ 18.31	$ (8.68)	$ 19.86	$ 28.74	$ 126.20	$ 58.27	$ 12.10
Income Tax Expense (Benefit)									$ (1,101,371)	$ (502,406)	$ (147,045)
Impairment losses on goodwill and long-lived assets									$ 0	$ 0	$ 292,513

18. Subsequent Event (Details)

18. Subsequent Event (Details) - Subsequent Event [Member] $ in Millions	Feb. 03, 2021USD ($)
Employee Severance [Member]
Subsequent Event [Line Items]
Restructuring and Related Cost, Expected Cost	$ 86
Other Restructuring [Member]
Subsequent Event [Line Items]
Restructuring and Related Cost, Expected Cost	19
Minimum [Member]
Subsequent Event [Line Items]
Restructuring and Related Cost, Expected Cost	125
Minimum [Member] | Other Restructuring [Member]
Subsequent Event [Line Items]
Restructuring and Related Cost, Expected Cost	20
Minimum [Member] | Employee Severance [Member]
Subsequent Event [Line Items]
Restructuring and Related Cost, Expected Cost	80
Maximum [Member]
Subsequent Event [Line Items]
Restructuring and Related Cost, Expected Cost	130
Maximum [Member] | Other Restructuring [Member]
Subsequent Event [Line Items]
Restructuring and Related Cost, Expected Cost	25
Maximum [Member] | Employee Severance [Member]
Subsequent Event [Line Items]
Restructuring and Related Cost, Expected Cost	$ 90